Papers¶
Every paper seen by the pipeline. 1032 total.
| Date | Title | Journal | Source | Links |
|---|---|---|---|---|
| 2026-04-20 | JAK inhibition in PD-1 immunotherapy and tumor microenvironment | Frontiers in immunology | pubmed | PMC |
| 2026-04-20 | Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy | Frontiers in immunology | pubmed | PMC |
| 2026-04-20 | Liquid biopsy in cancer drug resistance: real-time monitoring, mechanistic insights, and translational applications | Frontiers in immunology | pubmed | PMC |
| 2026-04-17 | Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance. | Signal transduction and targeted therapy | pubmed | PMID DOI |
| 2026-04-16 | COX-2 regulates IL-17A-producing γδ T cells to drive mismatch repair-deficient colon cancer | other_preprint | DOI | |
| 2026-04-15 | Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-04-15 | Regional immunosuppression and associated systemic markers in focally relapsed sarcomatoid mesothelioma: case report. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-15 | Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy. | Cellular oncology (Dordrecht, Netherlands) | pubmed | PMID DOI PMC |
| 2026-04-14 | Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy. | Research (Washington, D.C.) | pubmed | PMID DOI PMC |
| 2026-04-14 | Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond. | Journal of immunotherapy and precision oncology | pubmed | PMID DOI PMC |
| 2026-04-14 | Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives. | Gut microbes | pubmed | PMID DOI PMC |
| 2026-04-14 | Spatiotemporal immune dynamics in lung cancer progression and treatment. | Breathe (Sheffield, England) | pubmed | PMID DOI PMC |
| 2026-04-14 | Pulmonary toxicity of immune checkpoint inhibitors. | Breathe (Sheffield, England) | pubmed | PMID DOI PMC |
| 2026-04-13 | Tumor Organoid and Microenvironment Cocultures: Implications for Basic and Translational Cancer Research. | MedComm | pubmed | PMID DOI PMC |
| 2026-04-13 | Spatial omics for profiling the dynamic tumor microenvironment. | Clinical & translational immunology | pubmed | PMID DOI PMC |
| 2026-04-13 | Macrophage plasticity in the osteosarcoma tumor microenvironment: opportunities and challenges for immunotherapy. | Journal of cancer research and clinical oncology | pubmed | PMID DOI PMC |
| 2026-04-12 | Targeted Therapies for Each Subtype of Breast Cancer. | MedComm | pubmed | PMID DOI PMC |
| 2026-04-11 | Harnessing Proteogenomics to Advance Precision Oncology: From Melanoma and Hepatocellular Carcinoma Perspective. | Current oncology reports | pubmed | PMID DOI PMC |
| 2026-04-10 | Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond. | Signal transduction and targeted therapy | pubmed | PMID DOI PMC |
| 2026-04-10 | Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy. | Gut microbes | pubmed | PMID DOI PMC |
| 2026-04-10 | Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-10 | Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy. | Cancer communications (London, England) | pubmed | PMID DOI PMC |
| 2026-04-10 | Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025. | Cancer innovation | pubmed | PMID DOI PMC |
| 2026-04-10 | Dual Pathway Inhibition in Patients With mRCC: A Case Series From Kuwait Highlighting the Role of Avelumab and Axitinib. | Case reports in oncological medicine | pubmed | PMID DOI PMC |
| 2026-04-10 | Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-04-10 | Integrating machine learning and spatial transcriptomics uncovers shared immunomodulatory deubiquitinases in MAFLD and HCC. | Human genetics | pubmed | PMID DOI PMC |
| 2026-04-10 | Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | pubmed | PMID DOI |
| 2026-04-09 | Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report. | The American journal of case reports | pubmed | PMID DOI PMC |
| 2026-04-09 | Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer. | MedComm | pubmed | PMID DOI PMC |
| 2026-04-09 | Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-09 | Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-09 | Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-08 | Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment. | Oncoimmunology | pubmed | PMID DOI PMC |
| 2026-04-08 | Regulatory B Cells at the Crossroads of Epigenetic Control and Immune Homeostasis. | Clinical reviews in allergy & immunology | pubmed | PMID DOI PMC |
| 2026-04-07 | Advanced Mucosal Melanoma Therapies: Current Status and Future Directions. | Current treatment options in oncology | pubmed | PMID DOI PMC |
| 2026-04-07 | Messing with Signal 1: How Perturbed MHC Class I Antigen Presentation Contributes to Cancer. | Cells | pubmed | PMID DOI PMC |
| 2026-04-07 | Nanodelivery of Traditional Chinese Medicine Monomers: An Emerging Strategy to Reprogram the Immunosuppressive Tumor Microenvironment. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-04-07 | Triple-Negative Breast Cancer Brain Metastasis: A Comprehensive Review of Epidemiology, Molecular Pathobiology, and Therapeutic Frontiers. | Cancers | pubmed | PMID DOI PMC |
| 2026-04-06 | Comprehensive Analysis Based on the Cancer-Immunity Cycle Identifies a Novel Immunosuppressive Subtype of Bladder Cancer. | International journal of genomics | pubmed | PMID DOI PMC |
| 2026-04-06 | Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study. | Future oncology (London, England) | pubmed | PMID DOI |
| 2026-04-06 | Targeted hyperthermia therapy (THT) using gold nanorods remodels the tumor microenvironment to sensitize murine microsatellite-stable colorectal cancer to immune checkpoint blockade. | Journal of nanobiotechnology | pubmed | PMID DOI |
| 2026-04-06 | Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma. | Journal of molecular medicine (Berlin, Germany) | pubmed | PMID DOI PMC |
| 2026-04-06 | Hypoalbuminemia induces immunosuppression through disorder in macrophages and drives resistance to immune checkpoint inhibitors. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-04-05 | Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-04-05 | From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer. | European journal of cancer (Oxford, England : 1990) | pubmed | PMID DOI |
| 2026-04-05 | Prognostic Implications of Programmed Cell Death Ligand 1 Expression, Cluster of Differentiation 8-Positive T-Cell Infiltration, and Related Immunophenotypes in Invasive Mucinous Adenocarcinoma of the Lung: A Multicenter Study. | MedComm | pubmed | PMID DOI PMC |
| 2026-04-05 | Targeting SERPINE1 enhances PD-1 blockade response by modulating macrophage infiltration and polarization through the STAT3-CCL2 axis in non-small cell lung cancer. | International immunopharmacology | pubmed | PMID DOI |
| 2026-04-04 | Hemophagocytic Lymphohistiocytosis Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of Spontaneous Reports. | Cancers | pubmed | PMID DOI PMC |
| 2026-04-04 | The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases: Distinct Biology and Clinical Challenges. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-04-04 | Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling. | Expert opinion on biological therapy | pubmed | PMID DOI |
| 2026-04-03 | Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies. | Molecules (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-04-03 | The Prognostic Effect of Sarcopenia in Solid Cancers Treated with Immunotherapy: A Systematic Review and Meta-Analysis. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-04-03 | Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression. | Cancers | pubmed | PMID DOI PMC |
| 2026-04-03 | Pan-cancer landscape of protein kinase D3: An integrative TCGA multi-omics analysis of clinical, molecular, and immunological roles. | PloS one | pubmed | PMID DOI PMC |
| 2026-04-03 | TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-03 | EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-04-03 | Immune exhaustion in bacterial infections: mechanisms, consequences, and therapeutic implications. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases | pubmed | PMID DOI PMC |
| 2026-04-03 | Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-02 | Bright side of the dark genome: antigens for next-gen cancer vaccines. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-02 | Preventive strategies against brain metastases: current state of the art and future directions. | Neurological research and practice | pubmed | PMID DOI PMC |
| 2026-04-02 | Targeting the neuro-immune crosstalk in breast cancer brain metastases. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-02 | TIM-3 in AML: pathogenic roles and therapeutic targetability. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-04-02 | Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities. | Journal of biomedical science | pubmed | PMID DOI PMC |
| 2026-04-01 | Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer. | Journal of cardiovascular pharmacology | pubmed | PMID DOI PMC |
| 2026-04-01 | Targeting Tumor-Associated Macrophages and Cancer-Associated Fibroblasts to Overcome Therapeutic Resistance in Hepatocellular Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-04-01 | Non-small cell lung cancer research: advances and persistent challenges. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-04-01 | Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment. | Cancer immunology research | pubmed | PMID DOI PMC |
| 2026-04-01 | Biopharmaceuticals for Cancer Treatment: An Update | Cancer medicine | pubmed | PMC |
| 2026-04-01 | Precision immunotherapy for breast cancer: from biomarkers to clinical practice. | Cancer biology & medicine | pubmed | PMID DOI PMC |
| 2026-04-01 | Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report. | Cancer reports (Hoboken, N.J.) | pubmed | PMID DOI PMC |
| 2026-04-01 | Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-04-01 | Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025 | Cancer innovation | pubmed | PMC |
| 2026-04-01 | Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025. | Frontiers in endocrinology | pubmed | PMID DOI PMC |
| 2026-04-01 | KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-04-01 | Baseline Tumor Features and Systemic Immune Dynamics Underlying Efficacy in MSS Metastatic Colorectal Cancer Treated with Regorafenib, Ipilimumab, and Nivolumab. | Cancer immunology research | pubmed | PMID DOI PMC |
| 2026-04-01 | CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-04-01 | Plasminogen activator inhibitor-1 as an oncologic target: biology, therapeutic inhibitors, and clinical translation. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-04-01 | Immune Checkpoint Inhibitor-Induced Ureteritis and Cystitis in Patients With Lung Cancer and Uterine Malignancies: A Case Series and Literature Review. | Journal of immunotherapy (Hagerstown, Md. : 1997) | pubmed | PMID DOI PMC |
| 2026-04-01 | Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC: A meta-analysis based on RCTs. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-04-01 | Potential of small-molecule targeted drugs in combination with CAR-T cell therapy for hematologic lymphomas. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-04-01 | A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-04-01 | Efficacy of first-line immune checkpoint inhibitors in advanced non-small-cell lung cancer with or without brain metastases: a systematic review and network meta-analysis. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-04-01 | Cellular senescence in cancer immunology and potential therapeutic strategy. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-04-01 | Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-04-01 | Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens. | Cancer cytopathology | pubmed | PMID DOI PMC |
| 2026-04-01 | Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-04-01 | Emerging role of RNA modification reader YTHDF2 in hematopoiesis, immunity, and cancer. | MedScience | pubmed | PMID DOI PMC |
| 2026-04-01 | Advances in TROP2-targeted antibody-drug conjugates for breast cancer therapy: into the new era. | Cancer biology & medicine | pubmed | PMID DOI PMC |
| 2026-04-01 | Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-01 | EBV Genome Variations and Association With Diseases. | Journal of medical virology | pubmed | PMID DOI PMC |
| 2026-04-01 | The Regulation and Function of Hippo/YAP Pathway in Cancer. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | pubmed | PMID DOI PMC |
| 2026-04-01 | Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-04-01 | Integrative multi-omic analysis identified <i>ERBB2</i> mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer. | Cancer biology & medicine | pubmed | PMID DOI PMC |
| 2026-04-01 | PVT1-104aa derived from the 8q24 gene desert promotes colorectal cancer tumorigenesis. | Clinical and translational medicine | pubmed | PMID DOI PMC |
| 2026-03-31 | Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy. | Annals of hematology | pubmed | PMID DOI PMC |
| 2026-03-31 | Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-31 | Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials. | Oncotarget | pubmed | PMID DOI PMC |
| 2026-03-31 | Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in immunotherapy and biomarker potentials. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-03-31 | Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-31 | Cancer and aging: complex associations and therapeutic targets. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-03-31 | Editorial: Advancements in solid tumor immunotherapy: enhancing efficacy and overcoming resistance. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-31 | Hypoxic microenvironment in cancer: role in metabolic reprogramming. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-31 | Diagnostic and Therapeutic Applications of Exosomes in Lung Cancer. | Cells | pubmed | PMID DOI PMC |
| 2026-03-31 | Metabolic Programming of Tumor-Associated Macrophages in Head and Neck Squamous Cell Carcinoma: Implications for Innate Immunity and Therapeutic Response. | Biology | pubmed | PMID DOI PMC |
| 2026-03-31 | CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer. | BMJ oncology | pubmed | PMID DOI PMC |
| 2026-03-31 | Adult T-cell leukemia/lymphoma: molecular pathogenesis, emerging therapies, and future directions. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-31 | Advances in antimicrobial peptides: promising cancer treatments and vaccines. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-03-31 | Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-03-30 | Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-30 | Immune Checkpoint Inhibitor–Associated Myocarditis in Cancer Patients: A Systematic Review of Clinical Presentation, Management, and Outcomes | other_preprint | DOI | |
| 2026-03-30 | Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation. | OncoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-03-30 | Tumor exosomes impact functional hallmarks of cancer. | Cancer metastasis reviews | pubmed | PMID DOI PMC |
| 2026-03-30 | Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma. | Oncoimmunology | pubmed | PMID DOI PMC |
| 2026-03-30 | A Novel Strategy for Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer: Exploring the Efficacy and Safety of Anlotinib Combined with PD-1/PD-L1 Inhibitors. | OncoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-03-30 | Role of histone modifications in gastric cancer (Review) | International journal of oncology | pubmed | PMC |
| 2026-03-29 | Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-03-28 | The impact of PD-1 mutations on pembrolizumab binding: insights from molecular dynamics and MM-GBSA analysis. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-03-27 | Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients. | Biomarker research | pubmed | PMID DOI PMC |
| 2026-03-27 | Clinicopathological and molecular characteristics associated with pathological complete response in neoadjuvant immunotherapy for breast cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-27 | Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-27 | Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-27 | Tumor microenvironment-induced epigenetic reprogramming of Tregs and its impact on immunotherapy. | Frontiers in genetics | pubmed | PMID DOI PMC |
| 2026-03-27 | HMGB1 as Double-Edged Regulator of Cancer Therapy: Mechanistic Roles in Chemotherapy Resistance and Immunotherapy Response. | OncoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-03-27 | Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-03-27 | Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional Activation, Microenvironment Modulation, and Clinical Translation. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-27 | Role and clinical importance of lactylation in tumors (Review). | Molecular medicine reports | pubmed | PMID DOI PMC |
| 2026-03-27 | Key Considerations for Targeting <i>KRAS</i> in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. | Drug design, development and therapy | pubmed | PMID DOI PMC |
| 2026-03-27 | Discovery of tumor antigens in renal cell carcinoma and prospects for clinical application. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-27 | The mechanism of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma: current developments and future prospects. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-27 | Immunotherapy-based treatment patterns and clinical outcomes across lines of therapy in microsatellite stable metastatic colorectal cancer: A real-world study. | Oncology letters | pubmed | PMID DOI PMC |
| 2026-03-26 | Shaping next decade of systemic therapy for head and neck squamous cell carcinoma: where do we go next? | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-26 | Metformin enhances survival with immune checkpoint inhibitors in cancer patients: A meta-analysis. | Oncology letters | pubmed | PMID DOI PMC |
| 2026-03-26 | Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-26 | Integrin β3: structural functions, tumour microenvironment regulatory roles and targeted intervention strategies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-26 | Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-26 | Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | pubmed | PMID DOI |
| 2026-03-26 | Case Report: Olaparib combined with temozolomide and atezolizumab in a case of <i>BRCA2</i>-mutated small-cell transformation of lung adenocarcinoma. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-25 | Harmonizing yin and yang, remodeling the microenvironment: the adjuvant potential of Chinese herbal medicine in tumor immunotherapy. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-25 | Microbe-driven immune suppression in colorectal cancer: the <i>Fusobacterium nucleatum</i> playbook. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-25 | Multidimensional tumor heterogeneity and its role in therapeutic resistance. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-25 | Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-25 | Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-03-25 | Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-25 | The cGAS-STING pathway in cancer: friend or foe. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-03-25 | The prognostic value of the lung immune prognostic index in patients with urological cancers: a systematic review and meta-analysis. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-25 | Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-25 | Engineering the tumor microenvironment via 3D multicellular bioprinting for personalized immunotherapy assessment and resistance deciphering. | Hepatobiliary surgery and nutrition | pubmed | PMID DOI PMC |
| 2026-03-25 | PIK3CA mutation-induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-25 | Algorithmically defined therapeutic targets: integrating single-cell transfer learning frameworks with small molecule drugs to reverse disease-associated cell fates. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-03-24 | Translational advances in gastric cancer: integrating biomarkers, novel therapies, and microenvironment remodeling in 2025. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-03-24 | The gut microbiome as an actionable drug-sensitivity modulator for immune checkpoint blockade: clinical evidence for FMT, live biotherapeutics, and defined consortia. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-24 | Molecular Mechanisms in Oral Squamous Cell Carcinoma: Integrative Roles of Cancer-Associated Fibroblasts, Immune Microenvironment, and Precision Therapeutic Opportunities. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-24 | TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation. | Oncogene | pubmed | PMID DOI PMC |
| 2026-03-24 | Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-24 | Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-24 | Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-03-24 | Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-24 | Recombinant human adenovirus type 5 synergizes with anti-PD-L1 antibody to promote anti-hepatocellular carcinoma effects through multilevel remodeling of the immune microenvironment. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-24 | Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-23 | Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases. | Oncology research | pubmed | PMID DOI PMC |
| 2026-03-23 | Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma. | Oncology research | pubmed | PMID DOI PMC |
| 2026-03-23 | Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer. | Annals of medicine | pubmed | PMID DOI PMC |
| 2026-03-23 | Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications. | Oncology research | pubmed | PMID DOI PMC |
| 2026-03-23 | Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer. | Oncology research | pubmed | PMID DOI PMC |
| 2026-03-23 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-23 | Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-23 | From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery. | Materials today. Bio | pubmed | PMID DOI PMC |
| 2026-03-23 | Crosstalk between NRP1 and autophagy in the tumor microenvironment: from molecular mechanisms to therapeutic targeting. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-23 | γδ T cells at the interface of innate and adaptive immunity in cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-23 | Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-23 | Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-23 | Sphingosine-1-phosphate promotes CD8 T cell exhaustion in breast cancer via exosomal transfer of TGFBR2. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-03-23 | Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer. | Human vaccines & immunotherapeutics | pubmed | PMID DOI PMC |
| 2026-03-23 | Case Report: A rare case of Pneumocystis jirovecii infection with left hydropneumothorax following immunotherapy for stage IVB clear cell renal cell carcinoma. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-03-23 | Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-23 | Pancancer Analysis and the Oncogenic Role of <i>UBTF</i> in Breast Invasive Carcinoma. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-23 | Exploring the Role of GGA2 in Cancer Progression: Pan-Cancer Bioinformatics and Experimental Validation in Prostate Cancer. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-23 | Activation of endogenous retroviruses in tumor cells and their immunomodulatory mechanisms: from molecular basis to clinical translation. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-23 | DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy. | JCI insight | pubmed | PMID DOI PMC |
| 2026-03-23 | Comparative Retrospective Analysis of Immunotherapy Combined with Anti-Angiogenic Agents and Nab-Paclitaxel in Metastatic Gastroesophageal Junction Adenocarcinoma. | International journal of general medicine | pubmed | PMID DOI PMC |
| 2026-03-23 | Distinct biological and molecular characteristics of breast cancer in young women: a narrative review. | Annals of medicine and surgery (2012) | pubmed | PMID DOI PMC |
| 2026-03-22 | Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologies. | Drug delivery | pubmed | PMID DOI PMC |
| 2026-03-21 | Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review. | Journal of personalized medicine | pubmed | PMID DOI PMC |
| 2026-03-21 | Lactylation stabilizes PD-L1 to promote tumor immune evasion and cell growth. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-03-21 | Unveiling the prognostic and therapeutic landscape of the zinc transporter protein SLC39A family in colorectal cancer through multi-omics and machine learning approaches. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-03-20 | Advances in the application of multi-omics in tumor immunotherapy. | Frontiers in genetics | pubmed | PMID DOI PMC |
| 2026-03-20 | Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026. | Cells | pubmed | PMID DOI PMC |
| 2026-03-20 | Recent advances in drug repurposing for cancer immunomodulation emerging strategies, mechanistic insights, and clinical translation. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-20 | Melanoma leptomeningeal disease: Advances in diagnosis and emerging therapeutic strategies. | World journal of experimental medicine | pubmed | PMID DOI PMC |
| 2026-03-20 | Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-20 | Exosomes and cholangiocarcinoma: mechanisms, diagnostic, and therapeutic perspectives. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-20 | Bridging Inflammation and Oncology: The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-20 | Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-20 | The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-20 | TOPK Suppresses the CD8<sup>+</sup> T Cell Antitumor Immunity via Modulation of IRF5 Expression. | Cancer communications (London, England) | pubmed | PMID DOI PMC |
| 2026-03-20 | Research Progress on Anticancer Mechanism of Ginsenoside Regulating Tumor Microenvironment. | Current issues in molecular biology | pubmed | PMID DOI PMC |
| 2026-03-20 | Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-03-19 | The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application. | ImmunoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-03-19 | Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-19 | Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis. | Frontiers in cardiovascular medicine | pubmed | PMID DOI PMC |
| 2026-03-19 | An intriguing journey into the hereditary syndromes predisposing to endometrial cancer: more than believed. | Therapeutic advances in medical oncology | pubmed | PMID DOI PMC |
| 2026-03-19 | Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-19 | Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer. | Therapeutic advances in medical oncology | pubmed | PMID DOI PMC |
| 2026-03-19 | Overcoming immunotherapy resistance in breast cancer: a novel strategy by targeting the integrated stress response. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-19 | A Complete Response to Immunotherapy in a Patient with Locally Advanced Squamous Cell Lung Cancer Harboring a Novel <i>TMEM178B::BRAF</i> Fusion: A Case Report. | Diagnostics (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-03-19 | Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-19 | FLASH radiotherapy and immunotherapy synergy: mechanisms, strategies, and clinical translation prospects. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-19 | Epigenetic Regulators as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-19 | The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-19 | Humanized avian embryo models replicate an immune tumor environment for rapid immunotherapy studies. | EMBO molecular medicine | pubmed | PMID DOI PMC |
| 2026-03-19 | Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity. | Proceedings of the National Academy of Sciences of the United States of America | pubmed | PMID DOI PMC |
| 2026-03-19 | Dietary and Nutritional Strategies for Patients with Glioma: A Narrative Review of Treatment, Recovery, Immune Support, and Microbiota Modulation. | Nutrients | pubmed | PMID DOI PMC |
| 2026-03-19 | Bridging metabolic reprogramming and targeted therapy: the critical role of S-palmitoylation in cancer. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-19 | CAR T-cell therapy induced pseudoprogression. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-19 | Case Report: Successful treatment of steroid-refractory severe immunotherapy-induced pneumonitis with equine antithymocyte globulin. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-19 | Breast and ovarian cancers: toward a multi-cancer early detection test. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-19 | Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with Ipilimumab. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-03-19 | Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-18 | Next-generation immunotherapy biologics for glioblastoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-18 | Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-18 | Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-18 | Oncologic strategies and options for the management of metastatic thymic carcinoma. | Mediastinum (Hong Kong, China) | pubmed | PMID DOI PMC |
| 2026-03-18 | Lymphocyte function inhibition and exhaustion in sepsis: mechanisms and applications. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-18 | Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-18 | Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer. | Oncogenesis | pubmed | PMID DOI PMC |
| 2026-03-18 | Integration of immunogenic cell death in the treatment landscape of non-small cell lung cancer: harnessing the power of the immune system. | Cell death discovery | pubmed | PMID DOI PMC |
| 2026-03-18 | Immune checkpoint targeted drug conjugate therapies: Bridging preclinical and clinical innovation for solid tumor therapy. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | pubmed | PMID DOI |
| 2026-03-18 | Immune checkpoint inhibitors in children with replication-repair-deficient high-grade gliomas. The South London Paediatric & TYA Neuro-Oncology Network experience | other_preprint | DOI | |
| 2026-03-18 | CX3CR1 identifies a potent effector CD8<sup>+</sup> T cell subset associated with anti-PD-1 therapeutic efficacy in colorectal cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-18 | Outcomes and Safety of PD-1 Blockades Plus Anlotinib Regimen in Previously-Treated Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective, Exploratory Study. | Drug design, development and therapy | pubmed | PMID DOI PMC |
| 2026-03-18 | Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-18 | Dual Regulation of Post-Translational Modification of Proteins: Bottlenecks and Breakthroughs in NK Cell Therapy for Glioblastoma. | International journal of general medicine | pubmed | PMID DOI PMC |
| 2026-03-18 | <i>MET</i> amplification in diffuse pleural mesothelioma and response to savolitinib: a case report. | Translational lung cancer research | pubmed | PMID DOI PMC |
| 2026-03-18 | Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer. | Translational lung cancer research | pubmed | PMID DOI PMC |
| 2026-03-17 | Revisiting the Immune Frontier in Soft Tissue Sarcomas. | Current oncology reports | pubmed | PMID DOI PMC |
| 2026-03-17 | The Emerging Melanoma Management: Historical Perspective to Future Directions. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-17 | Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy. | Annals of medicine | pubmed | PMID DOI PMC |
| 2026-03-17 | Incidence of severe immune-related adverse reactions in patients with HIV and cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-17 | Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-03-17 | The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-03-17 | Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and PD-L1. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-17 | Advances in Spatial Multi-Omics in Gastric Cancer. | Cells | pubmed | PMID DOI PMC |
| 2026-03-17 | The microbiome: regulating anti-tumor immunity. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-17 | A review of the current evidence for maintenance therapy in gastric cancer. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-03-17 | Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer. | Journal of inflammation research | pubmed | PMID DOI PMC |
| 2026-03-17 | Reprogramming tumor-associated macrophages in DMG/DIPG: emerging molecular and biophysical strategies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-17 | Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-16 | Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-16 | The Role of the Ecto-Nucleotidases CD73 and CD39 in Chemo- and Immunotherapy. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-16 | Does immunotherapy hold great promise in endometrial cancer care? | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-16 | Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-03-16 | Chronic viral infections and their role in shaping the tumor immune microenvironment. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-16 | <i>TFE3</i>-Rearranged and <i>TFEB</i>-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-16 | Advances in protein ubiquitination modification and immune evasion of breast cancer. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-16 | T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses. | The Journal of clinical investigation | pubmed | PMID DOI PMC |
| 2026-03-15 | Liver Transplantation Following Immune Checkpoint Inhibitor Therapy: What Do We Need to Know from Clinical and Immunological Perspective? | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-15 | Molecular profile and targeted therapies for ovarian clear cell ovarian cancer. | Therapeutic advances in medical oncology | pubmed | PMID DOI PMC |
| 2026-03-14 | Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects | Frontiers in immunology | pubmed | PMC |
| 2026-03-14 | Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies | Frontiers in immunology | pubmed | PMC |
| 2026-03-14 | Dual PD-1 and CTLA-4 targeting in endometrial carcinoma: integrating efficacy, toxicity, and biomarkers into clinical practice | Frontiers in immunology | pubmed | PMC |
| 2026-03-14 | Ipilimumab, -omics, and head and neck cancers—update in 2025 | Frontiers in immunology | pubmed | PMC |
| 2026-03-14 | Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances | Molecular Biomedicine | pubmed | PMC |
| 2026-03-14 | Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions. | MedComm | pubmed | PMID DOI PMC |
| 2026-03-14 | TGF-β in hematologic malignancies: molecular functions and clinical applications | Frontiers in immunology | pubmed | PMC |
| 2026-03-14 | Immune checkpoint inhibitor-related encephalitis overlapping with hyperprogression in metastatic lung cancer: a case report | Frontiers in immunology | pubmed | PMC |
| 2026-03-14 | Epigenetic and mitoepigenetic regulation in cancer and therapeutic perspectives | Frontiers in pharmacology | pubmed | PMC |
| 2026-03-14 | Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer: from mechanistic exploration to clinical translation | Frontiers in immunology | pubmed | PMC |
| 2026-03-13 | Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. | Therapeutic advances in medical oncology | pubmed | PMID DOI PMC |
| 2026-03-13 | Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-13 | Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-03-13 | Aptamers targeting immune checkpoints for tumor immunotherapy: a comprehensive review. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-13 | Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-13 | Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy predictors, and therapeutic integration. | Chinese medical journal pulmonary and critical care medicine | pubmed | PMID DOI PMC |
| 2026-03-13 | Mitochondrial Quality Control and Metabolic Reprogramming in Hepatocellular Carcinoma: Implications for Immunotherapy and Treatment Resistance. | Cells | pubmed | PMID DOI PMC |
| 2026-03-13 | Photochemical enhancement of PD-L1-SAP immunotoxin efficacy in non-small cell lung cancer cell lines. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-13 | Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-03-13 | Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry. | Journal of neuro-oncology | pubmed | PMID DOI PMC |
| 2026-03-13 | First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies. | Targeted oncology | pubmed | PMID DOI PMC |
| 2026-03-13 | Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer. | Science advances | pubmed | PMID DOI PMC |
| 2026-03-13 | Systematic and precise interventions for KRAS-mutant cancers. | Experimental hematology & oncology | pubmed | PMID DOI PMC |
| 2026-03-12 | Regulation of immune checkpoints by electronic cigarette. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-12 | Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-03-12 | Post-Translational Regulation of CD8<sup>+</sup> T Cell Fate and Dysfunction in Tumor Immunity. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | pubmed | PMID DOI PMC |
| 2026-03-12 | Role of autophagy in tumorigenesis and drug resistance: molecular mechanisms and therapeutic targets. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-03-12 | Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies. | Cell death discovery | pubmed | PMID DOI PMC |
| 2026-03-12 | Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. | Pharmaceutics | pubmed | PMID DOI PMC |
| 2026-03-12 | Proliferative Tumor States and Immunogenic Ecosystems Predict Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-03-12 | Pivotal role of long non-coding RNA in the development of new therapeutic approaches for plural mesothelioma. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-03-11 | Small cell lung cancer: from immunobiological mechanisms to clinical advances. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | Aging modulation of the immune system and immunotherapy efficacy in cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-11 | BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-03-11 | Tumor Microenvironment and Immune Response Against Wilms Tumor: Evasion Mechanisms and Implications for Immunotherapeutic Approaches. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-11 | Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-03-11 | Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions. | Translational lung cancer research | pubmed | PMID DOI PMC |
| 2026-03-11 | The tumor microenvironment as a key regulator of radiotherapy response. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse model. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-11 | Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma. | Cancer biology & therapy | pubmed | PMID DOI PMC |
| 2026-03-11 | Complement system in cancer: friend or foe of immunotherapy. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-11 | Targeting the chemokine-Treg axes in tumor immune evasion: from mechanisms to therapeutic opportunities. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | The tumor microenvironment shapes gastric cancer progression by coordinating immune suppression and metabolic reprogramming. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | Post-translational protein lactylation modification in lung cancer: an emerging targeted therapeutic strategy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure. | ESMO open | pubmed | PMID DOI PMC |
| 2026-03-11 | Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-03-11 | Research progress on the roles of extracellular vesicles in tumor immunity and drug resistance. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-11 | Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer. | Cancers | pubmed | PMID DOI PMC |
| 2026-03-11 | C1RL-AS1/microRNA-424-5p/adrenoceptor β2 axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis. | PloS one | pubmed | PMID DOI PMC |
| 2026-03-10 | Effectiveness, safety, and the abscopal effect of stereotactic body radiation therapy combined with immune checkpoint inhibitors in advanced gastrointestinal cancers: a systematic review and meta-analysis. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-10 | Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-10 | Harnessing the immune microenvironment: advances in nasopharyngeal carcinoma immunotherapy. | Cell death discovery | pubmed | PMID DOI PMC |
| 2026-03-10 | Invariant Natural Killer T Cells in Cancer Immunotherapy: Lipid-Based Modulation, Nanotechnology, and Translational Advances. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-10 | Targeted delivery and controlled release of deferasirox for melanoma therapy. | iScience | pubmed | PMID DOI PMC |
| 2026-03-10 | Special Issue "New Molecular Mechanisms and Advanced Therapies for Solid Tumors". | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-03-10 | Cancer-associated fibroblast heterogeneity and its role in reshaping immunotherapy in solid cancers: potential strategies and clinical promise. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-10 | Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma. | Metabolites | pubmed | PMID DOI PMC |
| 2026-03-10 | Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets. | MedComm | pubmed | PMID DOI PMC |
| 2026-03-10 | AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-10 | Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-10 | Conquering aging-related immunosenescence and tumor immune escape. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-10 | The neural niche in cancer: mechanistic insights into tumor-neuron-immune crosstalk and therapeutic opportunities. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-10 | Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-03-09 | Vaccination in Oncology Patients: Evidence, Clinical Challenges, and Future Directions. | Vaccines | pubmed | PMID DOI PMC |
| 2026-03-09 | The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment. | Research (Washington, D.C.) | pubmed | PMID DOI PMC |
| 2026-03-09 | Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation. | Annals of medicine | pubmed | PMID DOI PMC |
| 2026-03-09 | Emerging role of lncRNA TP53TG1 as a tumor regulator and biomarker in human malignancies. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-03-08 | The Neutrophil-NET Axis in Immune Checkpoint Inhibitor Resistance in Non-Small Cell Lung Cancer: Roles, Biomarkers and Therapeutic Opportunities. | Biomolecules | pubmed | PMID DOI PMC |
| 2026-03-08 | Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. | IJU case reports | pubmed | PMID DOI PMC |
| 2026-03-07 | Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review. | Current urology reports | pubmed | PMID DOI PMC |
| 2026-03-07 | Macrophage-centered immunotherapy for osteosarcoma: mechanisms, repolarization, and translational strategies. | World journal of surgical oncology | pubmed | PMID DOI PMC |
| 2026-03-07 | Calibrating the RT-cGAS-STING axis to drive cold-to-hot tumor transformation: mechanistic foundations and translational strategies for combination with immunotherapy. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-03-07 | Spatially defined danger zone shapes gastric cancer progression through CCDC80<sup>+</sup> fibroblast-induced CD8<sup>+</sup> T cell dysfunction. | Apoptosis : an international journal on programmed cell death | pubmed | PMID DOI PMC |
| 2026-03-07 | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30<sup>+</sup> lymphomas. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-03-06 | Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies. | Current oncology reports | pubmed | PMID DOI PMC |
| 2026-03-06 | B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy. | Oncoimmunology | pubmed | PMID DOI PMC |
| 2026-03-06 | Advances in immunotherapy and targeted therapy for nasopharyngeal carcinoma: Current progress and combined approaches (Review). | Oncology reports | pubmed | PMID DOI PMC |
| 2026-03-06 | Dual roles of immunosenescence in cancer immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-06 | IL‑6: A key player in the EGFR‑TKI‑resistant tumor microenvironment and its therapeutic implications (Review). | International journal of oncology | pubmed | PMID DOI PMC |
| 2026-03-06 | Comparative Cancer Genetics and Veterinary Therapeutics in Dogs and Cats: A Species-Aware Framework for Comparative Oncology. | Life (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-03-06 | AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis. | iScience | pubmed | PMID DOI PMC |
| 2026-03-06 | Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells. | British journal of cancer | pubmed | PMID DOI PMC |
| 2026-03-06 | Next generation sequencing guided treatment of <i>ALK</i> tyrosine kinase inhibitor induced long survival in lung squamous cell carcinoma harboring <i>ROS1</i> gene fusions: a case report and literature review. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-03-06 | Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review). | International journal of oncology | pubmed | PMID DOI PMC |
| 2026-03-06 | Functional roles and mechanisms of NAT10-mediated RNA ac<sup>4</sup>C modification in normal development and cancer progression. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-03-06 | Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-06 | The impact of chronic comorbidities on cancer immunoediting: challenges and opportunities for immunotherapies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-06 | Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-03-06 | Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma. | Cancer communications (London, England) | pubmed | PMID DOI PMC |
| 2026-03-06 | Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-03-06 | Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy Outcomes. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-03-06 | The extracellular matrix in inflammation and cancer. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-03-05 | Strategies to target PD-1/PD-L1 in the tumor microenvironment. | Cellular oncology (Dordrecht, Netherlands) | pubmed | PMID DOI PMC |
| 2026-03-05 | Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-03-05 | Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-03-05 | Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances. | Current issues in molecular biology | pubmed | PMID DOI PMC |
| 2026-03-05 | Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies. | ImmunoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-03-05 | Immune Checkpoint Inhibitors and Bone Health: Mechanisms, Clinical Implications, and Emerging Perspectives on Bone Fragility. | Current osteoporosis reports | pubmed | PMID DOI PMC |
| 2026-03-05 | Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-05 | Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-05 | Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy. | Journal of liver cancer | pubmed | PMID DOI PMC |
| 2026-03-05 | Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-05 | TP53 Loss Fuels mTORC1 Activation and Autophagy Suppression to Drive Immune-Cold Colorectal Cancer. | World journal of oncology | pubmed | PMID DOI PMC |
| 2026-03-05 | Recent highlights and breakthroughs in immunotherapy for head and neck cancers. | Current opinion in oncology | pubmed | PMID DOI PMC |
| 2026-03-05 | Cell-type specificity of Tim-3 in respiratory diseases: from mechanisms to clinical translation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-05 | Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer. | World journal of oncology | pubmed | PMID DOI PMC |
| 2026-03-05 | The role of abnormal amino acid metabolism in the occurrence and development of tumors. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-05 | Clinicopathologic, molecular and tumor immune microenvironment features of mismatch repair-deficient glioblastomas in Lynch syndrome: a multicenter study of 29 cases with therapeutic implications. | Acta neuropathologica communications | pubmed | PMID DOI PMC |
| 2026-03-05 | Patient-derived d-MMR/MSI phenotype urachal cancer organoids for personalized drug screening. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-05 | Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results. | Cancer discovery | pubmed | PMID DOI PMC |
| 2026-03-04 | Immune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-04 | Advancing immune checkpoint inhibitor rechallenge: key insights into efficacy, safety, and personalized strategies in advanced solid tumors. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-04 | Hydrogel-Based Immunomodulation of Tumor Immune Microenvironment in Hepatocellular Carcinoma: Current Strategies and Future Directions. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-04 | The role of the tumor microenvironment in drug resistance acquisition in lung squamous cell carcinoma. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-03-04 | Antibody therapeutics with high affinity for FcγRs exacerbate anaphylaxis via FcγR-mediated capture by tumor-associated myeloid cells. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-04 | Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-03-04 | Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-04 | Challenges and advances in drug resistance and tolerance in cancer. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-03-04 | The dual regulatory role of METTL14-mediated m<sup>6</sup>A modification in tumorigenesis and its underlying mechanisms. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-04 | Clinical Application of Peripheral Blood Biomarkers for Solid Tumors. | MedComm | pubmed | PMID DOI PMC |
| 2026-03-04 | Reshaping the colorectal cancer immune microenvironment: insights from single-cell and spatial omics. | Cancer cell international | pubmed | PMID DOI PMC |
| 2026-03-04 | ERRα-ETV5 axis drives PD-L1 upregulation and immune escape in gallbladder cancer. | Cancer letters | pubmed | PMID DOI |
| 2026-03-04 | Spatial transcriptomics and artificial intelligence: a scoping review of emerging applications in head and neck pathology. | Head and neck pathology | pubmed | PMID DOI PMC |
| 2026-03-04 | A clinical decision framework for redox-adapted, EMT-high cancers: From ferroptosis resistance to precision therapeutic stratification. | Redox biology | pubmed | PMID DOI PMC |
| 2026-03-04 | Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1). | BMC cancer | pubmed | PMID DOI PMC |
| 2026-03-04 | Fluid-Derived Organoids from Pleural Effusion and Ascites: Emerging Models for Drug Resistance and Personalized Oncology. | Journal of Cancer | pubmed | PMID DOI PMC |
| 2026-03-04 | The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer. | International immunopharmacology | pubmed | PMID DOI |
| 2026-03-03 | A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-03 | Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: a comprehensive review. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-03 | Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study. | Cancer cell international | pubmed | PMID DOI PMC |
| 2026-03-03 | From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma. | Journal of personalized medicine | pubmed | PMID DOI PMC |
| 2026-03-03 | Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-03-03 | Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-03 | Comprehensive Pan-Cancer Analysis Reveals RNF20 as a Candidate Prognostic and Diagnostic Biomarker. | Bioinformatics and biology insights | pubmed | PMID DOI PMC |
| 2026-03-03 | Priorities for local immunotherapy research and drug development. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-03 | Charting the Current Landscape and Future Prospects of Cancer Therapy-Related Cardiovascular Toxicity in Cancer Survivors: From Bench to Bedside. | Drug design, development and therapy | pubmed | PMID DOI PMC |
| 2026-03-03 | Spatiotemporal control of immunogenic cell death: rewiring tumor-immune dialogues for next-generation immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-03 | SMARCA4-deficient non-small cell lung cancer and immunotherapy resistance: mechanisms and novel strategies-a mini-review. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-03-03 | Integrative genomic and immune landscape analysis of intimal sarcomas for emerging therapeutic targets and immunotherapy strategies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-03 | Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-03-03 | HPV status determines prognostic gene expression methylation and immune infiltration in head and neck squamous cell carcinoma. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-03-03 | Long noncoding RNA ADEI/miR-93-3p/STAT3 axis promotes Epstein-Barr virus-positive diffuse large B-cell lymphoma progression and immune evasion through regulating the PD-1/PD-L1 checkpoint. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-03-03 | Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-03-03 | Lactate metabolism and protein lactylation in colorectal cancer: from metabolic reprogramming to epigenetic regulation. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-03 | LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8<sup>+</sup> T-cell suppression. | Cellular and molecular life sciences : CMLS | pubmed | PMID DOI PMC |
| 2026-03-03 | Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-03-03 | Clinical and immunological implications of lymphocyte-activation gene 3 expression in metastatic colorectal cancer. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-03-03 | Correlation between gut microbiota and their metabolites and the efficacy of chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-03 | Polarization-Specific Macrophage-Derived Extracellular Vesicles: Molecular Cargo, Tumor Microenvironment Remodeling, and Therapeutic Opportunities. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-03-02 | Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-03-02 | Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer. | Pathology oncology research : POR | pubmed | PMID DOI PMC |
| 2026-03-02 | Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. | MedComm | pubmed | PMID DOI PMC |
| 2026-03-02 | Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-03-02 | Comprehensive machine learning identifies anoikis signatures predicting therapeutic resistance and survival in gastric cancer. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-03-02 | The changing landscape of urothelial carcinoma: on the edge of a paradigm shift | The Journal of clinical investigation | pubmed | PMC |
| 2026-03-02 | Targeting copper death-related long non-coding RNAs: a novel strategy to overcome immunotherapy resistance in liver cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-03-02 | Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects. | Journal of cell communication and signaling | pubmed | PMID DOI PMC |
| 2026-03-02 | KCTD1 stabilizes c-Myc to upregulate PD-L1 and suppress anti-tumor immunity in hepatocellular carcinoma. | Cell death discovery | pubmed | PMID DOI PMC |
| 2026-03-02 | Disrupting PDGFRA-driven immune evasion in glioma: vaccine-based strategies on the horizon. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-03-02 | Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-03-02 | Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers. | Journal of ovarian research | pubmed | PMID DOI PMC |
| 2026-03-01 | Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-03-01 | Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer | Cancers | pubmed | PMC |
| 2026-03-01 | Targeting tumor-infiltrating regulatory T cells based on immunometabolism. | Cancer biology & medicine | pubmed | PMID DOI PMC |
| 2026-03-01 | Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI | Cancers | pubmed | PMC |
| 2026-03-01 | Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy. | The oncologist | pubmed | PMID DOI PMC |
| 2026-03-01 | Immune checkpoint inhibitor-related acute kidney injury: A diagnostic and therapeutic challenge for nephrologists. | World journal of nephrology | pubmed | PMID DOI PMC |
| 2026-03-01 | A Silent Saboteur of Immunotherapy: Antibiotic Use and Its Impact on Immune Checkpoint Inhibitors Efficacy, a Systematic Review and Meta-Analysis of Recent Studies | Cancers | pubmed | PMC |
| 2026-03-01 | Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. | The oncologist | pubmed | PMID DOI PMC |
| 2026-03-01 | Heat up and Destroy: Immunotherapy of “Cold” Tumors Using the Example of Glioblastoma | International journal of molecular sciences | pubmed | PMC |
| 2026-03-01 | Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-03-01 | Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastases. | CA: a cancer journal for clinicians | pubmed | PMID DOI PMC |
| 2026-03-01 | When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-03-01 | Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. | Cancer immunology research | pubmed | PMID DOI PMC |
| 2026-03-01 | Drug Delivery Systems for Resiquimod to Control Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology | pubmed | PMID DOI PMC |
| 2026-03-01 | Editorial: Lung Cancer—From Mechanisms of Action and Risk Factors in Disease Onset to Management | Cancers | pubmed | PMC |
| 2026-03-01 | Molecular heterogeneity of HPV-associated cancers and strategies to overcome treatment resistance. | Cancer heterogeneity and plasticity | pubmed | PMID DOI PMC |
| 2026-03-01 | The Multifaceted Role of Androgen Receptor Signaling in Immunity: Implications for Oncology. | Molecular cancer research : MCR | pubmed | PMID DOI PMC |
| 2026-03-01 | Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions. | MedComm | pubmed | PMID DOI PMC |
| 2026-03-01 | Immune Network Construction and Prognostic Evaluation of Checkpoint Genes in Endometrial Cancer Using STRING, MCODE, and GEPIA2. | Cancer diagnosis & prognosis | pubmed | PMID DOI PMC |
| 2026-03-01 | Converging Pathways in Cancer Biology: How Do the Microbiome, Angiogenesis, Senescence, Fibroblast Plasticity, and Immunotherapy Intertwine? | Cancers | pubmed | PMC |
| 2026-03-01 | Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges | Chinese medical journal pulmonary and critical care medicine | pubmed | PMC |
| 2026-03-01 | Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations | International journal of molecular sciences | pubmed | PMC |
| 2026-03-01 | Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies. | The oncologist | pubmed | PMID DOI PMC |
| 2026-03-01 | Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. | Molecular cancer therapeutics | pubmed | PMID DOI PMC |
| 2026-03-01 | Translating Molecular Insights into Effective Targeting of Glioblastoma Stem Cells | Cancers | pubmed | PMC |
| 2026-03-01 | INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-03-01 | Scars That Speak: Unraveling the Oncogenic Aftermath of Pulmonary Tuberculosis—A Narrative Review | Journal of clinical medicine | pubmed | PMC |
| 2026-03-01 | Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. | The oncologist | pubmed | PMID DOI PMC |
| 2026-03-01 | The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-03-01 | ATR Blockade Potentiates the Effects of Genotoxic Agents In Vitro and Promotes Antitumor Immunity in a Mouse Model of Non-Small Cell Lung Cancer | Cancers | pubmed | PMC |
| 2026-03-01 | Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. | The New England journal of medicine | pubmed | PMID DOI PMC |
| 2026-03-01 | A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. | Japanese journal of clinical oncology | pubmed | PMID DOI PMC |
| 2026-02-28 | Poseidon’s Trident: “Divine” Intervention in Cervical Cancer Through Chemoradiation, Immunotherapy, and Antibody–Drug Conjugates | Cancers | pubmed | PMC |
| 2026-02-28 | TIGIT Blockade Potentiates the Anti-Leukemic Activity of Exercise-Mobilized Donor Lymphocytes and Expanded γδ T-Cells | Cancers | pubmed | PMC |
| 2026-02-28 | Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies | Cells | pubmed | PMC |
| 2026-02-28 | Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer. | Cell communication and signaling : CCS | pubmed | PMID DOI PMC |
| 2026-02-28 | Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective. | Biomarker research | pubmed | PMID DOI PMC |
| 2026-02-28 | Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-02-28 | Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-28 | Precision Diagnosis in Cutaneous Head and Neck Squamous Cell Carcinoma. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-02-27 | Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC | Immunological reviews | pubmed | PMC |
| 2026-02-27 | Targeting the gut microbiota-metabolite-immune axis in cancer immunotherapy: mechanistic interplay, therapeutic strategies, and translational applications-a narrative review. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-02-27 | First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. | Nature communications | pubmed | PMID DOI PMC |
| 2026-02-27 | PROTAC-based protein degradation: a window of opportunity for melanoma therapy. | Journal of biomedical science | pubmed | PMID DOI PMC |
| 2026-02-27 | Integrative analysis reveals the role of SUMOylation-related patterns in shaping the tumor microenvironment and predicting treatment sensitivity of colorectal cancer. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-02-27 | A2AR as a key target for immune microenvironment remodeling in prostate cancer. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-02-27 | Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial. | NPJ precision oncology | pubmed | PMID DOI PMC |
| 2026-02-27 | Severe edema as an immune-related adverse event following nivolumab therapy: a case report. | AME case reports | pubmed | PMID DOI PMC |
| 2026-02-27 | Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-27 | Angiogenesis-Informed Preoperative CT Radiogenomics Predicts Overall Survival in Clear Cell Renal Cell Carcinoma: Development and External Validation | Cancers | pubmed | PMC |
| 2026-02-26 | Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma | International journal of molecular sciences | pubmed | PMC |
| 2026-02-26 | Predicting skin melanoma progression via LAG-3, TIGIT and HAVCR2. | Functional & integrative genomics | pubmed | PMID DOI PMC |
| 2026-02-26 | Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions. | MedComm | pubmed | PMID DOI PMC |
| 2026-02-26 | Artificial Intelligence-Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance. | Journal of multidisciplinary healthcare | pubmed | PMID DOI PMC |
| 2026-02-26 | Tumorigenesis and Tumor Microenvironment in Lung Cancer. | Current issues in molecular biology | pubmed | PMID DOI PMC |
| 2026-02-26 | Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach. | Medical review (2021) | pubmed | PMID DOI PMC |
| 2026-02-26 | When Central Tolerance Fails: Thymic Malignancies at the Intersection of Cancer Immunity and Autoimmunity | Cancers | pubmed | PMC |
| 2026-02-26 | Immunotherapy for Cutaneous Squamous Cell Carcinoma in Aging Societies: Integrating Immunosenescence and Geriatric Oncology Perspectives | Cancers | pubmed | PMC |
| 2026-02-26 | Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-02-26 | PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signaling. | Cell death & disease | pubmed | PMID DOI PMC |
| 2026-02-26 | Metabolic-Immune Coupling in Urologic Cancers: Macrophage Reprogramming as a Therapeutic Nexus. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-02-26 | Systemic treatment strategies for combined hepatocellular-cholangiocarcinoma: current evidence and future direction. | Journal of liver cancer | pubmed | PMID DOI PMC |
| 2026-02-26 | Molecular classification and construction of prognostic risk model via machine learning based on metabolic-related genes in hepatocellular carcinoma. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-02-26 | Lactate metabolism and protein lactylation in cancer. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-02-26 | Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy | Cells | pubmed | PMC |
| 2026-02-26 | Global trends and research progress on immunotherapy for <i>EGFR</i>-mutant non-small cell lung cancer: a bibliometric analysis. | Journal of thoracic disease | pubmed | PMID DOI PMC |
| 2026-02-26 | Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial | Cell reports. Medicine | pubmed | PMC |
| 2026-02-26 | Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-26 | Tumor-associated CD19<sup>+</sup> macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma. | Nature communications | pubmed | PMID DOI PMC |
| 2026-02-26 | pH-neutralization strategy to suppress GPCR68 spatiotemporally activates T cells and enhances anti-tumor immunity. | Bioactive materials | pubmed | PMID DOI PMC |
| 2026-02-26 | Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects. | Frontiers in immunology | pubmed | PMID DOI |
| 2026-02-26 | Autophagy Modulation in Cancer Immunotherapy, Emerging Molecular Targets and Drug Selection Strategies | International journal of molecular sciences | pubmed | PMC |
| 2026-02-26 | Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancer. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-26 | Markers of immune activation and immunotherapy responsiveness are increased in 3D Pancreatic cancer organoids when primed with photodynamic- and chemo-therapy. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-02-25 | Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies. | Blood cancer journal | pubmed | PMID DOI PMC |
| 2026-02-25 | Tertiary lymphoid structures in genitourinary cancers: a comprehensive review. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-25 | Combined carbon ion radiotherapy and immunotherapy: leveraging the immunological advantages of carbon ion. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-25 | Pain spectrum in immune checkpoint inhibitor-related adverse events: evolution, characteristics and management challenges based on bibliometrics. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | pubmed | PMID DOI PMC |
| 2026-02-25 | Multiomics study on the tertiary lymphatic structure signature of colon cancer. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-02-25 | Targeted therapies in lung cancer: personalizing treatment across the age spectrum. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-25 | Commentary on "Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer". | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-25 | Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-25 | Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-25 | Gut microbiome in colorectal cancer: recent advances and clinical implications. | Annals of coloproctology | pubmed | PMID DOI PMC |
| 2026-02-25 | Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-02-25 | Self-reinforcing nanoplatform uniting pemetrexed, magnetic hyperthermia and PD-L1 blockade reshapes the tumor microenvironment and elicits combined antitumor immunity in lung adenocarcinoma. | Materials today. Bio | pubmed | PMID DOI PMC |
| 2026-02-25 | Ability of lactylation-related genes to stratify patients with ovarian cancer and predict immunotherapy response. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-02-25 | Pan-cancer analysis identifies FAM111B as a biomarker for immune suppression microenvironment in low-grade gliomas. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-02-24 | Overcoming resistance to immune checkpoint inhibitor therapy in acute myeloid leukemia. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-24 | Advances in Targeted and Immunotherapy for High-Risk Cutaneous Malignancies. | Oncology research | pubmed | PMID DOI PMC |
| 2026-02-24 | Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial. | Oncology research | pubmed | PMID DOI PMC |
| 2026-02-24 | The Role of B Cells in Tumorigenesis and Immunotherapy. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-24 | Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation | Cells | pubmed | PMC |
| 2026-02-24 | Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-24 | Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor". | Oncology research | pubmed | PMID DOI PMC |
| 2026-02-24 | A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. | Oncoimmunology | pubmed | PMID DOI PMC |
| 2026-02-24 | Molecular remodeling of cancer-associated fibroblasts in breast cancer patients receiving anti-PD-1 immunotherapy. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-24 | Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps. | Drug design, development and therapy | pubmed | PMID DOI PMC |
| 2026-02-24 | Histone deacetylases: Function in tumor development and therapeutic prospects (Review). | Oncology letters | pubmed | PMID DOI PMC |
| 2026-02-24 | The path forward for T cell engagers in patients with prostate cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-24 | The Neuroimmune Axis in Gastric Cancer: Bridging Neural Regulation, Tumor Microenvironment, and Immunotherapy. | Oncology research | pubmed | PMID DOI PMC |
| 2026-02-24 | <i>CEBPB</i> Expression in Tumor Cells Drives Immune Evasion in Colorectal Cancer via <i>CTLA4</i> Up-regulation in T Cells. | Cancer communications (London, England) | pubmed | PMID DOI PMC |
| 2026-02-24 | Evolving epidemiology and improving safety of rechallenge in immune checkpoint inhibitor-associated acute kidney injury: an updated meta-analysis. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-24 | The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-24 | Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies | Journal of clinical medicine | pubmed | PMC |
| 2026-02-24 | Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy. | Oncology research | pubmed | PMID DOI PMC |
| 2026-02-24 | The "serine code" of metabolic reprogramming: multidimensional roles of the serine synthesis pathway in tumors and novel breakthroughs for targeted therapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-24 | Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-02-24 | Mitophagy-driven multidimensional regulation of tumor immune evasion and context-dependent therapeutic strategies. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-24 | A Case of Metastatic Melanoma Refractory to Immunotherapy: Is Cytotoxic Chemotherapy Still an Effective Option? | Cureus | pubmed | PMID DOI PMC |
| 2026-02-24 | Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-02-23 | Tumor Cells as Architects of Immune Refractoriness: Dismantling Intrinsic Programs of Tumor Cells for Clinical Translation. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-23 | Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-23 | Multi-dimensional analysis reveals the potential of PDK4 as a tumor biomarker and target for immunotherapy. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-23 | NOTCH3 attenuates cytotoxicity via RBPJ-dependent PVR upregulation to influence immunotherapy outcomes in colorectal cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-23 | Integrating Three Functional Subsets of T Cell Immunity Into an Integrative Model for Cancer Immunotherapy. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-23 | Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis. | Annals of medicine | pubmed | PMID DOI PMC |
| 2026-02-23 | TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-23 | Analysis of cancer stem cell mechanism and immune profiling in breast cancer of unknown primary. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-23 | Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-23 | Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here. | Drugs | pubmed | PMID DOI PMC |
| 2026-02-23 | Epigenetic editing to advance CAR T cell therapy. | Clinical epigenetics | pubmed | PMID DOI PMC |
| 2026-02-22 | Periodontitis-Induced Immune Reprogramming: Implications for Cancer Immunotherapy Response. | Biomedicines | pubmed | PMID DOI PMC |
| 2026-02-22 | Nervous and immune system crosstalk shapes cancer progression and treatment response. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-21 | Epigenetic modulation to overcome immune suppression in pancreatic cancer. | Clinical epigenetics | pubmed | PMID DOI PMC |
| 2026-02-21 | Gut microbial signatures and immunotherapy outcomes in NSCLC and melanoma: a systematic review and meta-analysis. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-02-21 | Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab. | Oncology and therapy | pubmed | PMID DOI PMC |
| 2026-02-21 | Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities. | Human vaccines & immunotherapeutics | pubmed | PMID DOI PMC |
| 2026-02-21 | Mechanisms of resistance to bruton's tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways. | Annals of hematology | pubmed | PMID DOI PMC |
| 2026-02-20 | Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass). | Therapeutic advances in medical oncology | pubmed | PMID DOI PMC |
| 2026-02-20 | Targeting Telomerase in Cancer: Vaccine-Based Strategies, Clinical Evidence, and Synergy with Immunotherapy. | Diseases (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-02-20 | Immunotherapy in triple-negative breast cancer: From molecular mechanisms to precision medicine-overcoming resistance and optimizing clinical outcomes. | Critical reviews in oncology/hematology | pubmed | PMID DOI |
| 2026-02-20 | First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. | BMC medicine | pubmed | PMID DOI PMC |
| 2026-02-20 | Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC | Cell reports. Medicine | pubmed | PMC |
| 2026-02-20 | Lipid Metabolism Reprogramming in Diffuse Large B-Cell Lymphoma (DLBCL): Mechanisms and Treatment Strategies. | Cancers | pubmed | PMID DOI PMC |
| 2026-02-20 | Immuno-neural mechanisms in gastrointestinal tumorigenesis: bridging inflammation, neural regulation, and therapeutic innovation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-19 | Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors. | Cancer cell international | pubmed | PMID DOI PMC |
| 2026-02-19 | Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies. | Annals of coloproctology | pubmed | PMID DOI PMC |
| 2026-02-19 | Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer. | Biology | pubmed | PMID DOI PMC |
| 2026-02-19 | Regulatory T Cell Heterogeneity in the Steady State and Tumor. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-19 | Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-19 | Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-19 | CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-19 | Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-02-19 | Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer. | JCO precision oncology | pubmed | PMID DOI PMC |
| 2026-02-19 | Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies. | BMJ oncology | pubmed | PMID DOI PMC |
| 2026-02-19 | Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-19 | Progress in the research and development of oncolytic virus therapies. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-02-19 | Dual Roles of MAIT Cells in the Tumor Microenvironment: Implications for Cancer Immunity and Therapy. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-19 | Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-19 | Biomarkers and advances in AML-MRC: from bench to bedside. | Annals of hematology | pubmed | PMID DOI PMC |
| 2026-02-19 | ENPP3 drives ccRCC progression by cGAMP hydrolysis and STING-IFN suppression. | Cancer biology & therapy | pubmed | PMID DOI PMC |
| 2026-02-19 | Peritoneal carcinomatosis in metastatic Non-Small Cell Lung Cancer: review of the literature. | Cancer metastasis reviews | pubmed | PMID DOI PMC |
| 2026-02-19 | The non-classical immune checkpoint HLA-G: a regulatory master switch governing tolerance, evasion, and translational frontiers. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-18 | Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives. | Vaccines | pubmed | PMID DOI PMC |
| 2026-02-18 | Combining advanced radiotherapy techniques and immunotherapy: immunomodulatory mechanisms and clinical prospects. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-18 | The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance. | Blood science (Baltimore, Md.) | pubmed | PMID DOI PMC |
| 2026-02-18 | Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-18 | CAR-T cell immunotherapy in rhabdomyosarcoma. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-18 | Analysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-02-18 | Unraveling fibrinogen-like protein 1's role in immune regulation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-18 | Orchestrating Tumor Metastasis: Exosomes as Master Regulators of the Local and Distant Microenvironment. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-02-18 | Targeting regulated cell death pathways in lung cancer: mechanisms, therapeutic strategies, and clinical translation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-18 | Identification of programmed cell death-related subtypes reveals immune heterogeneity and therapeutic divergence in colon cancer. | Theranostics | pubmed | PMID DOI PMC |
| 2026-02-17 | Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-02-17 | Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI-H Tumors and Immune Checkpoint Inhibitors. | Health science reports | pubmed | PMID DOI PMC |
| 2026-02-17 | Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-02-17 | Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-02-17 | Decoding the archipelago: single-cell biomarkers rechart the molecular geography of acute myeloid leukemia. | Cell communication and signaling : CCS | pubmed | PMID DOI PMC |
| 2026-02-17 | CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation. | Cancer management and research | pubmed | PMID DOI PMC |
| 2026-02-17 | Immunometabolism in lung cancer - The link between metabolism and immune response. | iScience | pubmed | PMID DOI PMC |
| 2026-02-17 | First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours. | BMJ oncology | pubmed | PMID DOI PMC |
| 2026-02-17 | Readministration of nivolumab for patients with advanced gastric cancer: a case series. | ESMO gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-17 | Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. | Nature communications | pubmed | PMID DOI PMC |
| 2026-02-17 | Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma. | Nature communications | pubmed | PMID DOI PMC |
| 2026-02-16 | Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). | ESMO open | pubmed | PMID DOI PMC |
| 2026-02-16 | LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial. | Nature communications | pubmed | PMID DOI PMC |
| 2026-02-16 | Research progress on the correlation between OPN and immune escape of gastric cancer. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-16 | Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-16 | Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer. | ESMO open | pubmed | PMID DOI PMC |
| 2026-02-16 | NAT10 and ac4C modification in cancer immunity and metabolism: emerging mechanisms and therapeutic potential. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-16 | Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-02-15 | Deficient mismatch repair/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives. | BMJ oncology | pubmed | PMID DOI PMC |
| 2026-02-15 | Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-15 | BRAF mutation and tumor immune microenvironment in new era. | American journal of cancer research | pubmed | PMID DOI PMC |
| 2026-02-15 | Cytokine Profiling in Cutaneous Melanoma: The Emerging Role of Interleukins in Prognostic Stratification with an Up-to-Date Overview of Published Data. | Journal of personalized medicine | pubmed | PMID DOI PMC |
| 2026-02-15 | NK Cell Activation by Platinum Boosts Immunotherapy in HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | pubmed | PMID DOI PMC |
| 2026-02-15 | Steroid-Refractory Pembrolizumab-Induced Haemophagocytic Lymphohistiocytosis (HLH) Successfully Treated With Anakinra: A Case Report. | Cureus | pubmed | PMID DOI PMC |
| 2026-02-15 | Early Recognition of Immune-Related Hepatitis During Avelumab Maintenance Therapy for Urothelial Carcinoma. | IJU case reports | pubmed | PMID DOI PMC |
| 2026-02-14 | Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-14 | Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-14 | The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-13 | Immunotherapy advances in pleural mesothelioma. | Therapeutic advances in medical oncology | pubmed | PMID DOI PMC |
| 2026-02-13 | mRNA and Peptide Vaccines in Melanoma-Current Landscape and Future Direction. | Cells | pubmed | PMID DOI PMC |
| 2026-02-13 | Chorus line in oral squamous cell carcinoma: How stromal and immune players orchestrate tumor progression (Review). | International journal of molecular medicine | pubmed | PMID DOI PMC |
| 2026-02-13 | Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-13 | Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types. | Experimental hematology & oncology | pubmed | PMID DOI PMC |
| 2026-02-13 | Immunotherapy rechallenge after progression in non-small cell lung cancer: A systematic review and network meta-analysis. | iScience | pubmed | PMID DOI PMC |
| 2026-02-13 | Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer. | Human mutation | pubmed | PMID DOI PMC |
| 2026-02-13 | CHD4 epigenetically coordinates genomic instability and immunosuppression to drive pan-cancer progression and confer HDAC inhibitor sensitivity. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-13 | Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma. | JCO precision oncology | pubmed | PMID DOI PMC |
| 2026-02-13 | Synthetic lethality and DNA damage response targeting in cancer stem cells: a comprehensive review. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-13 | Obstructive sleep apnea and lung cancer: molecular underpinnings and clinical translational prospects. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-02-13 | Revisiting cholesterol metabolism in hepatocellular carcinoma: a hidden driver of systemic therapy response. | ESMO gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-12 | Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes. | Frontiers in medicine | pubmed | PMID DOI PMC |
| 2026-02-12 | Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-12 | First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-02-12 | Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer. | Cancer cell international | pubmed | PMID DOI PMC |
| 2026-02-12 | Editorial: Mechanisms and therapeutic opportunities of T-cell impairment in cancer immunity and immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-12 | Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in Sarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-02-12 | Balancing Intrinsic and Extrinsic Factors in CD8<sup>+</sup> T Cell Therapy. | Immune network | pubmed | PMID DOI PMC |
| 2026-02-12 | The Gut-Brain-Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities. | Cellular and molecular neurobiology | pubmed | PMID DOI PMC |
| 2026-02-12 | Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-12 | Successful treatment with tepotinib followed by pembrolizumab in pulmonary pleomorphic carcinoma harbouring a <i>MET</i> exon 14 skipping mutation: A case report. | Oncology letters | pubmed | PMID DOI PMC |
| 2026-02-12 | Higher proximity of PD-L1<sup>+</sup> tumor cells to PD-1<sup>+</sup> tissue-resident memory CD8 determines response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer. | Translational lung cancer research | pubmed | PMID DOI PMC |
| 2026-02-12 | The dual role of BRD9 in cancer: Mechanistic insights and therapeutic prospects. | iScience | pubmed | PMID DOI PMC |
| 2026-02-12 | C5aR1 and cGAS/STING and their possible involvement in radiosensitivity of colorectal cancer. | iScience | pubmed | PMID DOI PMC |
| 2026-02-12 | Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-12 | Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges. | Journal of gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-12 | Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-12 | Targeting NLRP3 inflammasome: a novel strategy for improving immune checkpoint inhibitor-associated pneumonitis. | Translational lung cancer research | pubmed | PMID DOI PMC |
| 2026-02-12 | C1QBP Associated With Immune Infiltration Predicts Poor Prognosis in Lung Adenocarcinoma. | Cancer informatics | pubmed | PMID DOI PMC |
| 2026-02-12 | ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8<sup>+</sup> T-cell immunity. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-02-12 | mRNA vaccines transform personalized lung cancer treatment. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-12 | Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-02-12 | Allostatic Load Predicts Immune-Related Toxicity and Survival in Melanoma Patients Receiving Immune Checkpoint Inhibitors. | Cancers | pubmed | PMID DOI PMC |
| 2026-02-12 | Fasting-mimicking diets as a strategy to reprogram tumor metabolism: a systematic review. | European journal of nutrition | pubmed | PMID DOI PMC |
| 2026-02-12 | IL-18-Mediated Tumor Immune Evasion. | Current issues in molecular biology | pubmed | PMID DOI PMC |
| 2026-02-12 | DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. | Journal of gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-12 | Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-02-12 | Interferon-gamma-inducible protein 30 prevents IFN-γ-receptor 1 degradation to maintain PD-L1 and MHC-II levels in metastatic melanoma. | Cell communication and signaling : CCS | pubmed | PMID DOI PMC |
| 2026-02-12 | Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory? | Journal of gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-11 | Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-11 | HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications. | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-11 | T-Cell Immunity and Lung Cancer. | Respirology (Carlton, Vic.) | pubmed | PMID DOI PMC |
| 2026-02-11 | Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer. | Experimental hematology & oncology | pubmed | PMID DOI PMC |
| 2026-02-11 | Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas. | Frontiers in neurology | pubmed | PMID DOI PMC |
| 2026-02-11 | Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-11 | The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis. | Human vaccines & immunotherapeutics | pubmed | PMID DOI PMC |
| 2026-02-11 | Single-cell dissection of hepatocellular carcinoma immunity: from heterogeneous subtypes to precision therapeutics. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-11 | DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-11 | Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-11 | NPLOC4 Inhibition Remodels Tumor Microenvironment via M2-to-M1 Macrophage Reprogramming and Boosts Anti-PD-1 Response in Liver Cancer. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-02-11 | Senescence-associated and immune-related 9p21.3 locus genes in colorectal cancer: epigenetic architecture, molecular landscape and therapeutic possibilities. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-02-11 | The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications. | Journal of hematology & oncology | pubmed | PMID DOI PMC |
| 2026-02-11 | Functional roles and mechanisms of circRNA-protein interactions in cancer progression and tumor immune regulation. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-11 | Molecular mechanisms and therapies for tumor inhibition through the arginine metabolism pathway. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-11 | AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | pubmed | PMID DOI PMC |
| 2026-02-11 | The avatar principle: exosomal dynamics guiding tumor adaptation and next-generation therapeutic strategies. | Journal of nanobiotechnology | pubmed | PMID DOI PMC |
| 2026-02-11 | Mechanisms of lactylation modification in hepatocellular carcinoma treatment resistance. | Gastroenterology report | pubmed | PMID DOI PMC |
| 2026-02-11 | Surufatinib plus tislelizumab as later-line therapy for metastatic colorectal cancer: a single-arm, phase II trial. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-02-11 | Immunobiological mechanisms of action of oncolytic peptides. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-11 | Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-10 | Preclinical exploration and current clinical applications of immunotherapeutic strategies for hepatocellular carcinoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | Urgent considerations on renal immune-related adverse events in oncology practice. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets. | Reviews in cardiovascular medicine | pubmed | PMID DOI PMC |
| 2026-02-10 | Biomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-10 | Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-10 | PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | IGSF9 promotes immunotherapy resistance in colon cancer by orchestrating an immunosuppressive tumor microenvironment and enables combinatorial targeting strategies. | Biochemistry and biophysics reports | pubmed | PMID DOI PMC |
| 2026-02-10 | Checkpoint inhibition in advanced biliary tract cancer: progress, limitations, and the search for biomarker-driven strategies. | Journal of gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-10 | The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | miRNA-driven cancer cell plasticity, tolerance and therapy resistance: lessons from melanoma. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-02-10 | Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies. | Journal of thoracic disease | pubmed | PMID DOI PMC |
| 2026-02-10 | Multi-omics analysis identifies TLRscore for prognostic prediction and highlights TLR8 in macrophage-mediated antitumor immunity of lung adenocarcinoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | Obstructive sleep apnea as a modifier of endocrine toxicities associated with immune checkpoint inhibitors in lung cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | Immune-related LncRNA signatures define tumor microenvironment subtypes and predict immunotherapy response in NSCLC. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-10 | Unlocking glioma vulnerabilities: targeting regulated cell death pathways for innovative therapies. | Cell death discovery | pubmed | PMID DOI PMC |
| 2026-02-10 | Programmed cell death inhibitors: a new hope for cancer therapy? | World journal of surgical oncology | pubmed | PMID DOI PMC |
| 2026-02-10 | Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer. | Acta oncologica (Stockholm, Sweden) | pubmed | PMID DOI PMC |
| 2026-02-10 | SMARCA4-Deficient Carcinomas of the Small Intestine: A Systematic Review. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-02-10 | HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-10 | The Oncogenic Role of Long Non-Coding RNA <i>NEAT1</i> in Head and Neck Squamous Cell Carcinoma: From Molecular Mechanisms to Clinical Implications. | Biology | pubmed | PMID DOI PMC |
| 2026-02-09 | Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy. | Pharmaceutical science advances | pubmed | PMID DOI PMC |
| 2026-02-09 | Unveiling trends and clinical progress of immunotherapy for endometrial cancer: a scientometric and clinical trial landscape analysis. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-09 | Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. | MedComm | pubmed | PMID DOI PMC |
| 2026-02-09 | OX40 signaling in cancer immunotherapy: mechanisms of action, translational applications, and therapeutic perspectives. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-09 | Semaphorins: from CD8⁺ T cells to cancer immunotherapy. | Biomarker research | pubmed | PMID DOI PMC |
| 2026-02-09 | Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-02-09 | Advancing the understanding of the immune escape in lung cancer immunotherapy: Global trends, collaborations, and future directions. | Human vaccines & immunotherapeutics | pubmed | PMID DOI PMC |
| 2026-02-09 | Glycolysis in the tumor microenvironment shapes dendritic cell function and antitumor immunity. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-09 | Sublethal heat stress synergizes with the tumor microenvironment to drive recurrence of hepatocellular carcinoma after thermal ablation: mechanisms, molecular predictors, and targeted interventions. | Cell biology and toxicology | pubmed | PMID DOI PMC |
| 2026-02-08 | Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response. | Experimental hematology & oncology | pubmed | PMID DOI PMC |
| 2026-02-08 | "Cytokine-Mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer Immunotherapy". | Clinical and experimental medicine | pubmed | PMID DOI PMC |
| 2026-02-08 | The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion. | Cells | pubmed | PMID DOI PMC |
| 2026-02-07 | Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-02-07 | High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-02-07 | Targeted therapies in pediatric oncology: A start. | Molecular therapy. Oncology | pubmed | PMID DOI PMC |
| 2026-02-07 | Mesothelin biology and the evolving landscape of targeted immunotherapy. | Molecular therapy. Oncology | pubmed | PMID DOI PMC |
| 2026-02-07 | Macrophage polarization in hematologic cancers: mechanisms and therapeutic strategies. | Blood research | pubmed | PMID DOI PMC |
| 2026-02-07 | Functionalized Biomaterials in the Investigation of the Effects of Fluid Shear Forces in the Immune Regulation of Cancer Progression and Metastasis. | Journal of functional biomaterials | pubmed | PMID DOI PMC |
| 2026-02-07 | Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-02-06 | Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future Directions. | Cancers | pubmed | PMID DOI PMC |
| 2026-02-06 | Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review. | Journal of Yeungnam medical science | pubmed | PMID DOI PMC |
| 2026-02-06 | The tumor microenvironment in leukemia: molecular pathways of immune evasion. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-06 | Clinical outcomes and safety of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer: a retrospective real-world study. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-06 | The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-06 | Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety. | mAbs | pubmed | PMID DOI PMC |
| 2026-02-06 | Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial. | Communications medicine | pubmed | PMID DOI PMC |
| 2026-02-06 | Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-02-06 | Long-term durable response to Sintilimab therapy in synchronous lung squamous cell carcinoma and gastric adenocarcinoma: a rare case report. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-06 | Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis. | European urology open science | pubmed | PMID DOI PMC |
| 2026-02-06 | Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. | Translational andrology and urology | pubmed | PMID DOI PMC |
| 2026-02-06 | Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-05 | Overcoming immune resistance in ovarian cancer: checkpoint inhibitors, tumor microenvironment, and translational advances. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-05 | Oncolytic viruses: advanced strategies in cancer therapy. | Signal transduction and targeted therapy | pubmed | PMID DOI PMC |
| 2026-02-05 | Advances in T cell-based immunotherapy for osteosarcoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-05 | Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies. | Frontiers in nutrition | pubmed | PMID DOI PMC |
| 2026-02-05 | Targeting urological cancers with CAR-T cell therapy: current landscape and future directions. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-02-05 | Diversity and function of tumor-associated macrophages in brain metastases: mechanisms and therapeutic prospects. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-05 | Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-02-05 | From local control to immune modulation: hypofractionated radiotherapy as a backbone for cancer immunotherapy. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-05 | Sialic acids modulate immune responses in cancer: Therapeutic opportunities. | The Journal of biological chemistry | pubmed | PMID DOI PMC |
| 2026-02-05 | MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial. | JHEP reports : innovation in hepatology | pubmed | PMID DOI PMC |
| 2026-02-05 | Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-02-05 | Circulating Tumor DNA in Melanoma: Advances in Detection, Clinical Applications, and Integration with Emerging Technologies. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-02-04 | Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-04 | Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-04 | Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges. | Targeted oncology | pubmed | PMID DOI PMC |
| 2026-02-04 | Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma. | ESMO gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-04 | Potent antitumor activity through dual targeting of PD-L1 and TGF-β pathways in the glioma tumor microenvironment. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-04 | Advancements in intratumoral therapies for liver tumors. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-04 | Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-04 | Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-02-04 | Applying biotechnology to overcome cancer drug resistance and improve public health outcomes. | Osong public health and research perspectives | pubmed | PMID DOI PMC |
| 2026-02-04 | Pleiotropic and multicellular roles of lymphotoxin beta receptor in solid tumor immunity and therapeutic targeting. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-04 | Writers and readers of sialylation in immunoregulation in cancer. | The Journal of biological chemistry | pubmed | PMID DOI PMC |
| 2026-02-04 | Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-02-04 | Recruitment of neutrophils by granulocyte colony-stimulating factor in cancer patients undergoing immunotherapy: the good, the bad, and the unknown. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-04 | A Comprehensive Review of Nanotechnological Innovations in Cancer: from Molecular Pathways to Clinical Applications. | Journal of Cancer | pubmed | PMID DOI PMC |
| 2026-02-03 | Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers. | Current oncology (Toronto, Ont.) | pubmed | PMID DOI PMC |
| 2026-02-03 | AlphaMissense pathogenicity scores predict response to immunotherapy and enhances the predictive capability of tumor mutation burden. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-02-03 | Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025). | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-03 | Regulating the regulators via targeting CD38 in the tumor microenvironment. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-03 | Targeting epigenetic regulators to boost T cell immunotherapy against cancer. | Cell & bioscience | pubmed | PMID DOI PMC |
| 2026-02-03 | Neutrophils in the hepatocellular carcinoma microenvironment: orchestrators of progression and immunity. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-03 | Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives. | Journal of hematology & oncology | pubmed | PMID DOI PMC |
| 2026-02-03 | Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-03 | The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-03 | AKR1B10 reprograms neutrophils by histone lactylation to foster immune evasion in KRAS<sup>G12C</sup> mutation colorectal cancer liver metastasis. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-02-03 | Decoding Microbiota in Genitourinary Oncology: Biological Mechanisms and Clinical Implications-A Narrative Review. | Cancers | pubmed | PMID DOI PMC |
| 2026-02-03 | Sexual dimorphism in cancer: molecular mechanisms and precision oncology perspectives. | Biology of sex differences | pubmed | PMID DOI PMC |
| 2026-02-03 | Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. | EBioMedicine | pubmed | PMID DOI PMC |
| 2026-02-03 | Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. | Cancers | pubmed | PMID DOI PMC |
| 2026-02-03 | Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | pubmed | PMID DOI PMC |
| 2026-02-03 | Methionine restriction in cancer: a dietary insight for therapy. | Frontiers in nutrition | pubmed | PMID DOI PMC |
| 2026-02-03 | Neutrophils in glioblastoma: orchestrators of the tumor microenvironment and immune evasion. | Molecular biology reports | pubmed | PMID DOI PMC |
| 2026-02-02 | Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer. | ImmunoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-02-02 | Microbiota in cancer: current understandings and future perspectives. | Signal transduction and targeted therapy | pubmed | PMID DOI PMC |
| 2026-02-02 | Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-02-02 | Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. | Advances in therapy | pubmed | PMID DOI PMC |
| 2026-02-02 | Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-02-02 | Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-02-02 | A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies. | Human vaccines & immunotherapeutics | pubmed | PMID DOI PMC |
| 2026-02-02 | Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1. | The Journal of clinical investigation | pubmed | PMID DOI PMC |
| 2026-02-02 | Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-02-02 | Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients: a meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-02-02 | The tumor microenvironment of cutaneous squamous cell carcinoma in high-risk patient groups: A scoping review. | JID innovations : skin science from molecules to population health | pubmed | PMID DOI PMC |
| 2026-02-02 | Copy-number amplification drives IFI30 overexpression and coordinated immune activation, identifying a novel diagnostic and therapeutic target in gastric adenocarcinoma. | Scientific reports | pubmed | PMID DOI PMC |
| 2026-02-02 | Integrated and clinical validation of helicase-like transcription factor as a biomarker for hepatocellular carcinoma. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-02-01 | T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy. | Journal of cellular and molecular medicine | pubmed | PMID DOI PMC |
| 2026-02-01 | Immunosuppressive Environment of Pancreatic NENs—A Review | Biomedicines | pubmed | PMC |
| 2026-02-01 | Evolution of Immune Checkpoint Blockade in Metastatic NSCLC: A Narrative Review of Emerging Bispecific Antibodies and the Practical Challenges of Clinical Integration | Cancers | pubmed | PMC |
| 2026-02-01 | Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets | Biomolecules | pubmed | PMC |
| 2026-02-01 | The Application of PD-1 Inhibitors in Immunotherapy for Glioblastoma. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | pubmed | PMID DOI PMC |
| 2026-02-01 | Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Scoping Review | Pharmaceuticals (Basel, Switzerland) | pubmed | PMC |
| 2026-02-01 | Molecular Pathogenesis and Targeted Treatment of Richter Transformation | Biomedicines | pubmed | PMC |
| 2026-02-01 | Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma | Cancers | pubmed | PMC |
| 2026-02-01 | Molecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment | Cancers | pubmed | PMC |
| 2026-02-01 | Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy | Cancers | pubmed | PMC |
| 2026-02-01 | CD4<sup>+</sup> T cells in cancer: dual roles, exhaustion, and therapeutic breakthroughs. | Cancer biology & medicine | pubmed | PMID DOI PMC |
| 2026-02-01 | Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis. | CPT: pharmacometrics & systems pharmacology | pubmed | PMID DOI PMC |
| 2026-02-01 | Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study. | Liver international : official journal of the International Association for the Study of the Liver | pubmed | PMID DOI PMC |
| 2026-02-01 | Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer. | World journal of gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent Strategies | Cancers | pubmed | PMC |
| 2026-02-01 | A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma. | Cancer | pubmed | PMID DOI PMC |
| 2026-02-01 | Clinical Characteristics and Predictive Factors of Immune-Mediated Cholangitis: A Large Single-Center Retrospective Observational Study | Cancers | pubmed | PMC |
| 2026-02-01 | Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study | Journal of clinical medicine | pubmed | PMC |
| 2026-02-01 | Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness | Cancers | pubmed | PMC |
| 2026-02-01 | Nasopharyngeal Carcinoma at the Virology Precision Oncology Nexus: Decoding Molecular Alterations for Early Intervention and Therapeutic Innovation | Biomolecules | pubmed | PMC |
| 2026-02-01 | Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | pubmed | PMID DOI PMC |
| 2026-02-01 | Perineural invasion in digestive tract tumors: Immune system interactions and therapeutic strategies. | World journal of clinical oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | Identification of a Tertiary Lymphoid Structure Signature for Predicting Tumor Outcomes Through Transcriptomics Analysis | Genes | pubmed | PMC |
| 2026-02-01 | Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T-cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite-Stable Colorectal Cancer. | Cancer research | pubmed | PMID DOI |
| 2026-02-01 | Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer. | Cancer immunology research | pubmed | PMID DOI PMC |
| 2026-02-01 | Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies. | World journal of clinical oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma | Cancers | pubmed | PMC |
| 2026-02-01 | Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab. | CPT: pharmacometrics & systems pharmacology | pubmed | PMID DOI PMC |
| 2026-02-01 | ICIsc: A Deep Learning Framework for Predicting Immune Checkpoint Inhibitor Response by Integrating scRNA-Seq and Protein Language Models | Bioengineering (Basel, Switzerland) | pubmed | PMC |
| 2026-02-01 | Molecular mechanisms of tumor-associated macrophages in hepatocellular carcinoma development and therapy. | World journal of gastroenterology | pubmed | PMID DOI PMC |
| 2026-02-01 | T cell immunity in glioma and potential implications for immunotherapy: A systematic review. | Neuro-oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | Integrating molecular and immune biomarkers for precision therapy in hepatitis B: Associated hepatocellular carcinoma. | World journal of hepatology | pubmed | PMID DOI PMC |
| 2026-02-01 | Do Metastatic Cells Arise from PD-L1+ Cell Niches in Gastric Adenocarcinoma? | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | Targeting Biliary Tract Cancers with Antibody–Drug Conjugates: Advances in Molecular Targets and Rational Combinations | Cancers | pubmed | PMC |
| 2026-02-01 | Antitumor Effects of PD-1 Blockade Combined with Mild Hyperthermia in a Murine Osteosarcoma Model | Biomedicines | pubmed | PMC |
| 2026-02-01 | First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients. | Cancer biology & medicine | pubmed | PMID DOI PMC |
| 2026-02-01 | Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer. | Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | pubmed | PMID DOI PMC |
| 2026-02-01 | Chemotherapy-Forward Management of Advanced Prostate Cancer: Taxane Timing, Sequencing and the Real-World Place of Immunotherapy | Cancers | pubmed | PMC |
| 2026-02-01 | The Bioinformatics and Experimental Analysis of CD276 for Prognosis and Immune Infiltrates in Colon Adenocarcinoma. | Cancer reports (Hoboken, N.J.) | pubmed | PMID DOI PMC |
| 2026-02-01 | Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure: a systematic review. | BMJ oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | Prediction of immunotherapeutic responses by a classifier model based on inflammation-associated tumor microenvironment signatures in colorectal cancer. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | Clear Cell and Histiocytic/Dendritic Cell Sarcomas: Clinical Outcomes, Molecular Features, and Diagnostic Pitfalls | Cancers | pubmed | PMC |
| 2026-02-01 | A Circulating Signature of Tumour Hybrid Cells and Immune Checkpoints Predicts Metastatic Progression in Lung Cancer | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | Innovations in Cutaneous Oncology and Dermatologic Surgery: From Margin Control to Integrated Precision Oncology | Cancers | pubmed | PMC |
| 2026-02-01 | Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-02-01 | Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-02-01 | deltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types. | Clinical and translational medicine | pubmed | PMID DOI PMC |
| 2026-02-01 | Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments | International journal of molecular sciences | pubmed | PMC |
| 2026-02-01 | Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer | Cancers | pubmed | PMC |
| 2026-02-01 | Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference | Biomolecules | pubmed | PMC |
| 2026-02-01 | Treatment-Related and Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor-Based Combination Therapies for Breast Cancer: A Systematic Review and Meta-Analysis. | Thoracic cancer | pubmed | PMID DOI PMC |
| 2026-02-01 | Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions. | World journal of clinical oncology | pubmed | PMID DOI PMC |
| 2026-01-31 | Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-31 | Current Treatment Standards for Metastatic Uveal Melanoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-31 | Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets. | MedComm | pubmed | PMID DOI PMC |
| 2026-01-31 | The Role of CCR1 as a decisive factor for immune response activation versus suppression phenotypes in gastric cancer. | Neoplasia (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2026-01-30 | Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-30 | JAK/STAT-mediated regulation of PD-L1 expression in breast cancer: Molecular mechanisms and implications for immunotherapy. | iScience | pubmed | PMID DOI PMC |
| 2026-01-30 | JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. | Future oncology (London, England) | pubmed | PMID DOI PMC |
| 2026-01-30 | TGF-β in tumor development and progression: mechanisms and therapeutics. | Molecular biomedicine | pubmed | PMID DOI PMC |
| 2026-01-30 | Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review and meta-analysis. | EXCLI journal | pubmed | PMID DOI PMC |
| 2026-01-30 | Research progress on traditional Chinese medicine-assisted immune checkpoint inhibitors therapy for solid tumors. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-30 | Reproductive Toxicity of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: A Case Report with a Literature Review. | Diseases (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-01-30 | Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-30 | Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-30 | Intra-tumoural microenvironment and bugs-based drug design: foreseeable future in oncology and immuno-oncology. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-01-30 | Spatial Omics in Gastrointestinal Oncology: Recent Advances, Therapeutic Insights, and Clinical Translation. | Journal of Cancer | pubmed | PMID DOI PMC |
| 2026-01-30 | FAPα<sup>+</sup> Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | pubmed | PMID DOI PMC |
| 2026-01-30 | The role of CD26 in breast cancer and its pan-cancer analysis. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-01-30 | Rewriting the RNA code: an m<sup>6</sup>a-centric framework to classify tumors and guide combination therapies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-30 | Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm. | The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology | pubmed | PMID DOI PMC |
| 2026-01-30 | Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-30 | A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-30 | PD-L1/<i>CD274</i> and miR-155<i>/MIR155HG</i> Genetic Variants as Prognostic and Risk Biomarkers in Diffuse Large B-Cell Lymphoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-30 | Expression profile of GSDMB in oral squamous cell carcinoma and its impact on tumor immune microenvironment and prognosis. | BMC oral health | pubmed | PMID DOI PMC |
| 2026-01-30 | Defining the role of natural killer cells in acute myeloid leukemia through the lens of single-cell omics. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-30 | Partial-EMT in oral squamous cell carcinoma: molecular circuitry and clinical translation. | International journal of oral science | pubmed | PMID DOI PMC |
| 2026-01-30 | Strategies, Challenges and Application Prospects for Exosome Engineering Modifications in Tumor Targeted Therapeutics. | International journal of nanomedicine | pubmed | PMID DOI PMC |
| 2026-01-29 | Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-29 | Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold Melanoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-29 | Spatial profiling of the metabolism-immune axis in ovarian cancer. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-01-29 | T cell immunotherapy for solid tumors: limitations, progress, and future prospects. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-29 | Advancing ICOS agonism in solid tumors: lessons from INDUCE-1. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-29 | Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions. | Vaccines | pubmed | PMID DOI PMC |
| 2026-01-29 | Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-29 | Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy. | Cellular oncology (Dordrecht, Netherlands) | pubmed | PMID DOI PMC |
| 2026-01-29 | IDO family: the metabolic crossroads connecting immunity, nerves and tumors. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-01-29 | Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer. | Breast cancer research : BCR | pubmed | PMID DOI PMC |
| 2026-01-29 | Tertiary lymphoid structures in renal cell carcinoma: from heterogeneity dissection to translational precision immunotherapy. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-28 | Unexpected Therapeutic Implications: The Abscopal Effect in the Management of Hepatocellular Carcinoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-28 | Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer. | Annals of medicine | pubmed | PMID DOI PMC |
| 2026-01-28 | Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review. | Rambam Maimonides medical journal | pubmed | PMID DOI PMC |
| 2026-01-28 | The molecular mechanisms of pyroptosis and its implications in tumor immunotherapy. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-28 | Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence | Biomedicines | pubmed | PMC |
| 2026-01-28 | ABCB5: A Key Regulator Linking Stem Cell Plasticity, Tumor Microenvironment, and Therapy Resistance in Cutaneous Melanoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-28 | Targeting the Tumor Microenvironment in Triple-Negative Breast Cancer: Emerging Roles of Monoclonal Antibodies and Immune Modulation. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-28 | Impact of immunotherapy and small molecule cancer therapy on fertility: a narrative review of current evidence, mechanisms and future directions. | BMJ oncology | pubmed | PMID DOI PMC |
| 2026-01-28 | Spatially resolved tryptophan-kynurenine niches in HNSCC: immunometabolic microdomains and therapeutic implications. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-28 | Tumor-Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation. | MedComm | pubmed | PMID DOI PMC |
| 2026-01-28 | Modulating the gut microbiome to enhance cancer immunotherapy: a systematic review and Meta-Analysis of probiotics and FMT as adjuncts. | BMC cancer | pubmed | PMID DOI PMC |
| 2026-01-28 | Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-28 | Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-28 | Acupuncture combined with immunotherapy for recurrent and metastatic cervical cancer: a pilot RCT protocol. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-01-28 | Antigen-specific T Cell precursor frequency influences the proliferation of stem-like T Cells in tumor-draining lymph nodes and anti-tumor immune responses. | Frontiers in molecular biosciences | pubmed | PMID DOI PMC |
| 2026-01-28 | RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-01-28 | SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-28 | Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-27 | Application of artificial intelligence in head and neck squamous cell carcinoma. | Annals of medicine | pubmed | PMID DOI PMC |
| 2026-01-27 | Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers. | Molecular therapy. Oncology | pubmed | PMID DOI PMC |
| 2026-01-27 | Deciphering the intratumor microbiota in malignant gastrointestinal tumors: multifaceted interplay and clinical implications. | Cell communication and signaling : CCS | pubmed | PMID DOI PMC |
| 2026-01-27 | Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-27 | Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer. | ESMO open | pubmed | PMID DOI PMC |
| 2026-01-27 | Rewiring tumor-associated macrophages in hepatocellular carcinoma. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-27 | Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-27 | Mechanisms and intervention strategies of microenvironment-mediated drug resistance in multiple myeloma. | Cancer cell international | pubmed | PMID DOI PMC |
| 2026-01-27 | Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade. | Nature medicine | pubmed | PMID DOI PMC |
| 2026-01-27 | Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-01-27 | Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-01-27 | Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy. | Nanomaterials (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-01-27 | Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-27 | Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-27 | Bevacizumab in biliary tract cancer: a clinical catalyst in the era of chemo-immunotherapy? | Journal of gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-01-27 | Identification of necrosis-related signature for predicting prognosis and immunotherapy response in gastric cancer. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-01-27 | Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-01-27 | Paroxetine repurposing enhances antitumor immunity via SPOP-mediated PD-L1 ubiquitination and proteasomal degradation. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-01-27 | Multi-omics analysis links <i>FERMT1</i> expression to patient survival, immunotherapy response, and metastasis across cancers. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-01-27 | Targeting cancer stem cells as the most aggressive and tumor-initiating cells. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-01-27 | Therapeutic application of IL-12 for cancer therapy. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-01-27 | FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy. | Discover oncology | pubmed | PMID DOI PMC |
| 2026-01-27 | Lactate-lactylation in tumor angiogenesis and progression: mechanisms, biomarker potential, and therapeutic implications. | Biomarker research | pubmed | PMID DOI PMC |
| 2026-01-27 | New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication. | World journal of surgical oncology | pubmed | PMID DOI PMC |
| 2026-01-27 | Subgroup-specific predictive biomarkers in peripheral blood lymphocyte subsets for immune checkpoint inhibitor response in advanced esophageal squamous cell carcinoma: a prospective study. | Journal of thoracic disease | pubmed | PMID DOI PMC |
| 2026-01-27 | Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation. | The Journal of clinical investigation | pubmed | PMID DOI PMC |
| 2026-01-27 | Targeting mitochondrial homeostasis as a cancer treatment strategy: current status and future prospects. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-27 | Identification and Validation of an Autophagy-Related Gene Signature for Prognostic Prediction and Immunotherapy Response in Esophageal Squamous Cell Carcinoma. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-27 | Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-01-27 | Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges. | Cancer immunology, immunotherapy : CII | pubmed | PMID DOI PMC |
| 2026-01-26 | Drug Therapy for Melanoma: Current Updates and Future Prospects. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-26 | Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-01-26 | Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications. | Signal transduction and targeted therapy | pubmed | PMID DOI PMC |
| 2026-01-26 | Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma. | Open medicine (Warsaw, Poland) | pubmed | PMID DOI PMC |
| 2026-01-26 | Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-01-26 | Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio. | Translational lung cancer research | pubmed | PMID DOI PMC |
| 2026-01-26 | Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab. | JGH open : an open access journal of gastroenterology and hepatology | pubmed | PMID DOI PMC |
| 2026-01-26 | Spatiotemporal dynamics of tumor-associated neutrophils: bridging the gap between cancer progression and immunotherapy. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-26 | TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-01-26 | Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-01-26 | Does the B7-H3 Immune Checkpoint Have High Potential as a Therapeutic Target? | Cells | pubmed | PMID DOI PMC |
| 2026-01-25 | Ferroptosis induction enhances anti-PD-1 efficacy in NSCLC via HIF-1α/PD-L1 modulation. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-01-25 | Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers. | Current issues in molecular biology | pubmed | PMID DOI PMC |
| 2026-01-24 | Neoadjuvant therapy in skin cancer: current evidence and future perspectives. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | pubmed | PMID DOI PMC |
| 2026-01-24 | Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology. | Naunyn-Schmiedeberg's archives of pharmacology | pubmed | PMID DOI |
| 2026-01-24 | From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas. | Cellular and molecular neurobiology | pubmed | PMID DOI PMC |
| 2026-01-24 | CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy. | NPJ breast cancer | pubmed | PMID DOI PMC |
| 2026-01-24 | ACLY blockade rewires tumor metabolism to boost immunity in MASH-driven hepatic cell carcinoma. | Journal of the National Cancer Center | pubmed | PMID DOI PMC |
| 2026-01-24 | Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy. | International journal of biological macromolecules | pubmed | PMID DOI |
| 2026-01-24 | Cancer-associated fibroblasts: enablers of tumor drug resistance. | Journal of translational medicine | pubmed | PMID DOI PMC |
| 2026-01-24 | POSTN⁺ cancer-associated fibroblast-CCL3⁺ macrophage crosstalk defines the immune-excluded tumor microenvironment in clear cell renal cell carcinoma. | Translational oncology | pubmed | PMID DOI PMC |
| 2026-01-23 | Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-23 | New insights into the tumor immune microenvironment and immunotherapy of thyroid cancer. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-23 | MYC at the tumor-immune interface: mechanisms of immune escape and immunotherapy resistance. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-23 | The Immune Biology of the Adrenal Gland Microenvironment and Its Role in Metastatic Progression. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-01-23 | The Influence of Molecular Factors on the Effectiveness of New Therapies in Endometrial Cancer-Latest Evidence and Clinical Trials. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-23 | Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy. | Liver cancer | pubmed | PMID DOI PMC |
| 2026-01-23 | Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-23 | Risk Factors and Biomarkers for Immune Checkpoint Inhibitor-mediated Hepatotoxicity: Emerging Insights and Future Perspectives. | Journal of clinical and translational hepatology | pubmed | PMID DOI PMC |
| 2026-01-23 | Key immune cells in the tumor immune microenvironment of colorectal cancer: Roles and research advances (Review). | Oncology reports | pubmed | PMID DOI PMC |
| 2026-01-23 | Immunotherapy Response Predictive Score Based on Tumor Microenvironment Profiles for Predicting Immunotherapy Outcomes in Advanced Head and Neck Cancer. | Technology in cancer research & treatment | pubmed | PMID DOI PMC |
| 2026-01-23 | Global advances and future directions in lung cancer care: expert consensus and strategic priorities. | ESMO open | pubmed | PMID DOI PMC |
| 2026-01-23 | Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature. | International journal of molecular sciences | pubmed | PMID DOI PMC |
| 2026-01-23 | Deciphering the CAF‑LCN2 axis: Key to overcoming anti‑PD‑L1 immunotherapy resistance in lung cancer. | International journal of molecular medicine | pubmed | PMID DOI PMC |
| 2026-01-23 | m<sup>6</sup>A RNA modification and myeloid-derived suppressor cells: mechanistic insights and clinical prospects. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-23 | A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-22 | Pipe dream to pipeline: Journey of cancer vaccines and the road ahead. | Cell reports. Medicine | pubmed | PMID DOI PMC |
| 2026-01-22 | Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025. | ESMO gastrointestinal oncology | pubmed | PMID DOI PMC |
| 2026-01-22 | Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-01-22 | Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-01-22 | Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-22 | Repurposing Itraconazole in Combination with Chemotherapy and Immune Checkpoint Inhibitor for Cancer. | Medical sciences (Basel, Switzerland) | pubmed | PMID DOI PMC |
| 2026-01-22 | Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy. | Acta pharmaceutica Sinica. B | pubmed | PMID DOI PMC |
| 2026-01-22 | Durvalumab-associated membranous nephropathy: a case report and brief literature review. | CEN case reports | pubmed | PMID DOI PMC |
| 2026-01-22 | The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy. | Cancer communications (London, England) | pubmed | PMID DOI PMC |
| 2026-01-22 | O-glycosylation in Cancer: Emerging Paradigms and Prospects for Precision Oncology. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-01-22 | Metabolic Checkpoints in CD8<sup>+</sup> T Cells within the Tumor Microenvironment: A Comprehensive Review and Emerging Insights. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-01-22 | Targeted Induction of Cancer Cell Necroptosis Potentiates Anti-PD-1 Immunotherapy via CD80 Activation. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-01-22 | Reprogrammed Fibrotic Niche Fuels Lung Cancer Initiation and Reciprocal Remodeling. | International journal of biological sciences | pubmed | PMID DOI PMC |
| 2026-01-22 | Intrapatient variation in PD-L1 expression and tumor mutational burden and implications for outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. | Journal for immunotherapy of cancer | pubmed | PMID DOI PMC |
| 2026-01-22 | Smart nanoplatforms for early detection and immune modulation in lung cancer. | Frontiers in bioengineering and biotechnology | pubmed | PMID DOI PMC |
| 2026-01-21 | Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma. | Oncoimmunology | pubmed | PMID DOI PMC |
| 2026-01-21 | Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-21 | Towards the tumor microenvironment scoring methods for immune checkpoint inhibitor response. | NPJ precision oncology | pubmed | PMID DOI PMC |
| 2026-01-21 | Emerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-01-21 | The ubiquitination-autophagy axis in cancer therapy resistance: mechanistic insights and therapeutic opportunities. | Frontiers in pharmacology | pubmed | PMID DOI PMC |
| 2026-01-21 | Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology. | Cancers | pubmed | PMID DOI PMC |
| 2026-01-21 | Advances in the application of tumor vaccines and combination strategies: new perspectives in lung cancer treatment. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-21 | Lactylation in cancer: molecular mechanisms and advances in clinical study. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-21 | Bibliometric analysis of ovarian cancer immune evasion research from 2015 to 2024. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-01-21 | A Retrospective Study on the Clinical Characteristics and Management of Immune-Related Adverse Events in Gynecologic Cancer Patients Treated with Immune Checkpoint Inhibitors. | ImmunoTargets and therapy | pubmed | PMID DOI PMC |
| 2026-01-21 | Editorial: Precision oncology in checkpoint immunotherapy: leveraging predictive biomarkers for personalized treatment. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-21 | KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. | Journal of clinical medicine | pubmed | PMID DOI PMC |
| 2026-01-21 | Targeting KIF20A: a new frontier in cancer treatment revealed by multi-omics analysis. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-21 | Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy. | Cell reports. Medicine | pubmed | PMID DOI PMC |
| 2026-01-20 | Tumor microenvironment-guided targeted and immunotherapy in anaplastic thyroid cancer: a literature review from preclinical models to clinical translation. | Translational cancer research | pubmed | PMID DOI PMC |
| 2026-01-20 | Tumor Immunotherapy and Microbiome: From Bench-to-Bedside Applications. | MedComm | pubmed | PMID DOI PMC |
| 2026-01-20 | The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review. | Journal of thoracic disease | pubmed | PMID DOI PMC |
| 2026-01-20 | Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review. | Annals of hematology | pubmed | PMID DOI PMC |
| 2026-01-20 | Research status and prospects of molecular pathological mechanisms and novel therapeutic targets of osteosarcoma: a systematic review. | Frontiers in oncology | pubmed | PMID DOI PMC |
| 2026-01-20 | Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target. | Cancer letters | pubmed | PMID DOI PMC |
| 2026-01-20 | Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics. | Molecular cancer | pubmed | PMID DOI PMC |
| 2026-01-20 | Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer. | ESMO open | pubmed | PMID DOI PMC |
| 2026-01-20 | Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy. | NPJ precision oncology | pubmed | PMID DOI PMC |
| 2026-01-20 | A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma. | Frontiers in cell and developmental biology | pubmed | PMID DOI PMC |
| 2026-01-20 | GLUT1 expression, lymphocyte distribution and CD3<sup>+</sup> T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma. | Journal of experimental & clinical cancer research : CR | pubmed | PMID DOI PMC |
| 2026-01-20 | Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024. | Frontiers in immunology | pubmed | PMID DOI PMC |
| 2026-01-20 | Camrelizumab Combined with Gemcitabine and Albumin-Bound Paclitaxel in Pancreatic Cancer Patients with Liver Metastases: A Prospective, Pilot Trial. | Drug design, development and therapy | pubmed | PMID DOI PMC |
| 2026-01-20 | Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | pubmed | PMID DOI PMC |
| 2021-02-01 | Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2020-12-10 | Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. | Science (New York, N.Y.) | pubmed | PMID DOI |
| 2020-12-01 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. | The New England journal of medicine | pubmed | PMID DOI |
| 2019-06-17 | TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. | Nature | pubmed | PMID DOI PMC |
| 2019-01-08 | Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. | Immunity | pubmed | PMID DOI |
| 2018-11-01 | Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. | Cell | pubmed | PMID DOI PMC |
| 2018-08-06 | Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. | Nature medicine | pubmed | PMID DOI |
| 2018-05-17 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. | Cancer discovery | pubmed | PMID DOI PMC |
| 2018-02-14 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | pubmed | PMID DOI PMC |
| 2018-02-14 | TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. | Nature | pubmed | PMID DOI |
| 2018-01-04 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2017-11-02 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2017-11-02 | Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. | Science (New York, N.Y.) | pubmed | PMID DOI |
| 2017-10-26 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. | Cell | pubmed | PMID DOI PMC |
| 2017-07-19 | In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. | Nature | pubmed | PMID DOI PMC |
| 2017-06-08 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2017-02-01 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | pubmed | PMID DOI PMC |
| 2017-01-01 | Elements of cancer immunity and the cancer-immune set point. | Nature | pubmed | PMID DOI |
| 2016-11-30 | Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. | Cancer discovery | pubmed | PMID DOI PMC |
| 2016-10-08 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. | The New England journal of medicine | pubmed | PMID DOI |
| 2016-07-13 | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. | The New England journal of medicine | pubmed | PMID DOI PMC |
| 2016-03-17 | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. | Cell | pubmed | PMID DOI PMC |
| 2015-12-08 | Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Cancer discovery | pubmed | PMID DOI PMC |
| 2015-11-05 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2015-11-05 | Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2015-05-31 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. | The New England journal of medicine | pubmed | PMID DOI PMC |
| 2015-05-11 | Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. | Nature | pubmed | PMID DOI |
| 2015-03-12 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science (New York, N.Y.) | pubmed | PMID DOI PMC |
| 2014-11-19 | Genetic basis for clinical response to CTLA-4 blockade in melanoma. | The New England journal of medicine | pubmed | PMID DOI PMC |
| 2014-11-01 | PD-1 blockade induces responses by inhibiting adaptive immune resistance. | Nature | pubmed | PMID DOI PMC |
| 2012-06-02 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | The New England journal of medicine | pubmed | PMID DOI PMC |
| 2010-06-05 | Improved survival with ipilimumab in patients with metastatic melanoma. | The New England journal of medicine | pubmed | PMID DOI PMC |